WO2012086184A1 - ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 - Google Patents
ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 Download PDFInfo
- Publication number
- WO2012086184A1 WO2012086184A1 PCT/JP2011/007111 JP2011007111W WO2012086184A1 WO 2012086184 A1 WO2012086184 A1 WO 2012086184A1 JP 2011007111 W JP2011007111 W JP 2011007111W WO 2012086184 A1 WO2012086184 A1 WO 2012086184A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- general formula
- reference example
- compound represented
- reaction
- Prior art date
Links
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical class C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 166
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 22
- 125000005843 halogen group Chemical group 0.000 claims abstract description 13
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 16
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 16
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 16
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 16
- 206010040047 Sepsis Diseases 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 8
- 208000005333 pulmonary edema Diseases 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010030043 Ocular hypertension Diseases 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 206010072810 Vascular wall hypertrophy Diseases 0.000 claims description 6
- 206010003119 arrhythmia Diseases 0.000 claims description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 208000018631 connective tissue disease Diseases 0.000 claims description 6
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 6
- 208000030533 eye disease Diseases 0.000 claims description 6
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 6
- 230000000302 ischemic effect Effects 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000006601 tracheal stenosis Diseases 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 5
- 208000002927 Hamartoma Diseases 0.000 claims description 5
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims description 5
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 5
- 206010062952 diffuse panbronchiolitis Diseases 0.000 claims description 5
- 206010050685 Cytokine storm Diseases 0.000 claims description 4
- 206010061323 Optic neuropathy Diseases 0.000 claims description 4
- 230000008602 contraction Effects 0.000 claims description 4
- 208000020911 optic nerve disease Diseases 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 206010051739 Pulmonary sepsis Diseases 0.000 claims description 3
- PWIZXECNEDCDMN-NRFANRHFSA-N [(2s)-2-amino-2-[2-[2-chloro-4-(5-ethoxy-2-hydroxyphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(OCC)=CC=C1O PWIZXECNEDCDMN-NRFANRHFSA-N 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 abstract 3
- 101710155457 Sphingosine 1-phosphate receptor 3 Proteins 0.000 abstract 3
- 238000011160 research Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
- 238000006243 chemical reaction Methods 0.000 description 97
- 239000000243 solution Substances 0.000 description 93
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- 239000000047 product Substances 0.000 description 44
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 36
- 238000003786 synthesis reaction Methods 0.000 description 36
- -1 S1P3 Proteins 0.000 description 35
- 239000002904 solvent Substances 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000001914 filtration Methods 0.000 description 21
- 239000012230 colorless oil Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 238000001816 cooling Methods 0.000 description 17
- 238000010898 silica gel chromatography Methods 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 13
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 230000003042 antagnostic effect Effects 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000007810 chemical reaction solvent Substances 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 0 CC(CCc(c(*)c1)ccc1Sc1cc(*)ccc1*)=O Chemical compound CC(CCc(c(*)c1)ccc1Sc1cc(*)ccc1*)=O 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 8
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 7
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 150000007530 organic bases Chemical class 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 6
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 6
- 206010047163 Vasospasm Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 239000012160 loading buffer Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 5
- 239000012300 argon atmosphere Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 5
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 229920001992 poloxamer 407 Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100029803 Sphingosine 1-phosphate receptor 4 Human genes 0.000 description 2
- 101710155458 Sphingosine 1-phosphate receptor 4 Proteins 0.000 description 2
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000004849 alkoxymethyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 150000002941 palladium compounds Chemical class 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- XHUCVFRMSAASBZ-QVDQXJPCSA-N (2r)-3,6-dimethoxy-2-propan-2-yl-5-propyl-2,5-dihydropyrazine Chemical compound CCCC1N=C(OC)[C@@H](C(C)C)N=C1OC XHUCVFRMSAASBZ-QVDQXJPCSA-N 0.000 description 1
- JJPFXNGOHGFLFK-XLIONFOSSA-N (2r,5r)-5-[2-(4-bromo-2-chlorophenyl)ethyl]-3,6-dimethoxy-2-propan-2-yl-5-prop-2-enyl-2h-pyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=N[C@@]1(CC=C)CCC1=CC=C(Br)C=C1Cl JJPFXNGOHGFLFK-XLIONFOSSA-N 0.000 description 1
- RLWOWWFVNKMZPU-YLJYHZDGSA-N (2r,5r)-5-[2-(4-bromo-2-chlorophenyl)ethyl]-3,6-dimethoxy-2-propan-2-yl-5-propyl-2h-pyrazine Chemical compound C=1C=C(Br)C=C(Cl)C=1CC[C@@]1(CCC)N=C(OC)[C@@H](C(C)C)N=C1OC RLWOWWFVNKMZPU-YLJYHZDGSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- DIWKDNYVEXJOQV-UHFFFAOYSA-N 1-cyclopropyl-4-(methoxymethoxy)benzene Chemical compound C1=CC(OCOC)=CC=C1C1CC1 DIWKDNYVEXJOQV-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- HJFGRXXBCDISJZ-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxy-2-sulfanylphenol Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=C(O)C(S)=C1 HJFGRXXBCDISJZ-UHFFFAOYSA-N 0.000 description 1
- FYOIKHJHYDLNJY-UHFFFAOYSA-N 4-bromo-2-chloro-1-(2-iodoethyl)benzene Chemical compound ClC1=CC(Br)=CC=C1CCI FYOIKHJHYDLNJY-UHFFFAOYSA-N 0.000 description 1
- IGIWPHRUBXKMAR-UHFFFAOYSA-N 4-cyclopropylphenol Chemical compound C1=CC(O)=CC=C1C1CC1 IGIWPHRUBXKMAR-UHFFFAOYSA-N 0.000 description 1
- CGMJYWDBLOFABI-UHFFFAOYSA-N 4-ethoxy-2-sulfanylphenol Chemical compound CCOC1=CC=C(O)C(S)=C1 CGMJYWDBLOFABI-UHFFFAOYSA-N 0.000 description 1
- XSVSPKKXQGNHMD-UHFFFAOYSA-N 5-bromo-3-methyl-1,2-thiazole Chemical compound CC=1C=C(Br)SN=1 XSVSPKKXQGNHMD-UHFFFAOYSA-N 0.000 description 1
- UEHCOZQUSPJNRV-UHFFFAOYSA-N 5-cyclopropyl-2-(methoxymethoxy)benzenethiol Chemical compound C1=C(S)C(OCOC)=CC=C1C1CC1 UEHCOZQUSPJNRV-UHFFFAOYSA-N 0.000 description 1
- VOYXPVUWCDXOGX-UHFFFAOYSA-N 6-[tert-butyl(dimethyl)silyl]oxy-1,3-benzoxathiol-2-one Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=C2SC(=O)OC2=C1 VOYXPVUWCDXOGX-UHFFFAOYSA-N 0.000 description 1
- MPJLMJRVYTZZCU-UHFFFAOYSA-N 6-ethoxy-1,3-benzoxathiol-2-one Chemical compound CCOC1=CC=C2SC(=O)OC2=C1 MPJLMJRVYTZZCU-UHFFFAOYSA-N 0.000 description 1
- 206010058040 Abdominal sepsis Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000653759 Homo sapiens Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SKNZLZLTCXEODB-QFIPXVFZSA-N N[C@@](CCCO)(CCc(ccc(Sc(cc(C1CC1)cc1)c1O)c1)c1Cl)CO[O](O)(O)O Chemical compound N[C@@](CCCO)(CCc(ccc(Sc(cc(C1CC1)cc1)c1O)c1)c1Cl)CO[O](O)(O)O SKNZLZLTCXEODB-QFIPXVFZSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 description 1
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 1
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XMLQXVUTAJBDLD-NRFANRHFSA-N [(2s)-2-[2-[4-(5-acetyl-2-hydroxyphenyl)sulfanyl-2-chlorophenyl]ethyl]-2-aminopentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C(C)=O)=CC=C1O XMLQXVUTAJBDLD-NRFANRHFSA-N 0.000 description 1
- MVHJNXUAEOBQGG-FQEVSTJZSA-N [(2s)-2-amino-2-[2-[2-chloro-4-(5-cyano-2-hydroxyphenyl)sulfanylphenyl]ethyl]pentyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)COP(O)(O)=O)=CC=C1SC1=CC(C#N)=CC=C1O MVHJNXUAEOBQGG-FQEVSTJZSA-N 0.000 description 1
- IXVGNJHXVOUPBS-QFIPXVFZSA-N [(3s)-3-amino-3-[2-[2-chloro-4-(5-ethoxy-2-hydroxyphenyl)sulfanylphenyl]ethyl]hexyl]phosphonic acid Chemical compound C1=C(Cl)C(CC[C@@](N)(CCC)CCP(O)(O)=O)=CC=C1SC1=CC(OCC)=CC=C1O IXVGNJHXVOUPBS-QFIPXVFZSA-N 0.000 description 1
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- NOXYEXFQXDRHTA-UHFFFAOYSA-N [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1 Chemical compound [O-2].[O-2].[O-2].[Cr+3].[Cr+3].C1=CC=NC=C1 NOXYEXFQXDRHTA-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- XAVFZUKFLWOSOS-UHFFFAOYSA-N bis(dimethoxyphosphoryl)methane Chemical compound COP(=O)(OC)CP(=O)(OC)OC XAVFZUKFLWOSOS-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- PPTSBERGOGHCHC-UHFFFAOYSA-N boron lithium Chemical compound [Li].[B] PPTSBERGOGHCHC-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001218 inhibitory effect on sepsis Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- NCPHGZWGGANCAY-UHFFFAOYSA-N methane;ruthenium Chemical compound C.[Ru] NCPHGZWGGANCAY-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 150000003409 sphingosine 1-phosphates Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XAAYZNKJDNAJEV-XIFFEERXSA-N tert-butyl [2-[3-chloro-4-[(3s)-3-(dimethoxyphosphoryloxymethyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexyl]phenyl]sulfanyl-4-ethoxyphenyl] carbonate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC)=CC=C1OC(=O)OC(C)(C)C XAAYZNKJDNAJEV-XIFFEERXSA-N 0.000 description 1
- OUYIWHPJPPZWPC-SFHVURJKSA-N tert-butyl n-[(3r)-1-(4-bromo-2-chlorophenyl)-3-(hydroxymethyl)hex-5-en-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@](CO)(CC=C)CCC1=CC=C(Br)C=C1Cl OUYIWHPJPPZWPC-SFHVURJKSA-N 0.000 description 1
- RNRAWWOXWRNDFG-GOSISDBHSA-N tert-butyl n-[(3r)-1-(4-bromo-2-chlorophenyl)-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@](CO)(CCC)CCC1=CC=C(Br)C=C1Cl RNRAWWOXWRNDFG-GOSISDBHSA-N 0.000 description 1
- XDTQROOIWHBEFI-VPTMLEGASA-N tert-butyl n-[(3r)-1-[2-chloro-4-[5-cyclopropyl-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(dimethoxyphosphoryloxymethyl)-4-hydroxyhexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](C(O)CC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C2CC2)=CC=C1OCOC XDTQROOIWHBEFI-VPTMLEGASA-N 0.000 description 1
- OCHKQFAQRDVLOC-SANMLTNESA-N tert-butyl n-[(3s)-1-[2-chloro-4-(5-ethoxy-2-hydroxyphenyl)sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC)=CC=C1O OCHKQFAQRDVLOC-SANMLTNESA-N 0.000 description 1
- NDOAGUAYYFNOBN-LJAQVGFWSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-cyano-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(dimethoxyphosphoryloxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C#N)=CC=C1OCOC NDOAGUAYYFNOBN-LJAQVGFWSA-N 0.000 description 1
- LUGJTGPAKYTSGU-MHZLTWQESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-cyano-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C#N)=CC=C1OCOC LUGJTGPAKYTSGU-MHZLTWQESA-N 0.000 description 1
- JPMKKNORADSKCA-HKBQPEDESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-ethoxy-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(2-dimethoxyphosphorylethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(CCP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC)=CC=C1OCOC JPMKKNORADSKCA-HKBQPEDESA-N 0.000 description 1
- CWLYRHICXIYNMM-NDEPHWFRSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-ethoxy-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(OCC)=CC=C1OCOC CWLYRHICXIYNMM-NDEPHWFRSA-N 0.000 description 1
- MUSVCOXSVCUKKR-NDEPHWFRSA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-ethoxy-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-formylhexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CCC)(NC(=O)OC(C)(C)C)C=O)=CC=C1SC1=CC(OCC)=CC=C1OCOC MUSVCOXSVCUKKR-NDEPHWFRSA-N 0.000 description 1
- WRFOSLOOEGGGSK-SANMLTNESA-N tert-butyl n-[(3s)-1-[2-chloro-4-[5-hydroxy-2-(methoxymethoxy)phenyl]sulfanylphenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(O)=CC=C1OCOC WRFOSLOOEGGGSK-SANMLTNESA-N 0.000 description 1
- AMBFXNMEVDIPDA-PMERELPUSA-N tert-butyl n-[(3s)-1-[4-[5-acetyl-2-(methoxymethoxy)phenyl]sulfanyl-2-chlorophenyl]-3-(dimethoxyphosphoryloxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@@](CCC)(COP(=O)(OC)OC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(C)=O)=CC=C1OCOC AMBFXNMEVDIPDA-PMERELPUSA-N 0.000 description 1
- NDOLQEGYNVGPOU-NDEPHWFRSA-N tert-butyl n-[(3s)-1-[4-[5-acetyl-2-(methoxymethoxy)phenyl]sulfanyl-2-chlorophenyl]-3-(hydroxymethyl)hexan-3-yl]carbamate Chemical compound C1=C(Cl)C(CC[C@](CO)(CCC)NC(=O)OC(C)(C)C)=CC=C1SC1=CC(C(C)=O)=CC=C1OCOC NDOLQEGYNVGPOU-NDEPHWFRSA-N 0.000 description 1
- IWXDXDCALKLIKB-UHFFFAOYSA-N tert-butylperoxycarbonyl (2-methylpropan-2-yl)oxy carbonate Chemical compound CC(C)(C)OOC(=O)OC(=O)OOC(C)(C)C IWXDXDCALKLIKB-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4015—Esters of acyclic unsaturated acids
Definitions
- the present invention relates to a novel diphenyl sulfide derivative or a salt thereof or a hydrate thereof useful as a medicament, and a sphingosine-1-phosphate 3 (S1P3) receptor antagonist and a medicament containing them as an active ingredient.
- S1P3 sphingosine-1-phosphate 3
- Sphingosine-1-phosphate S1P was considered to be only an intermediate metabolite in sphingosine metabolism. However, it has been reported to have a cell growth promoting effect and a cell motility control effect, and it is clear that this is a new lipid mediator that exhibits various physiological effects such as apoptosis, cell shape regulation, and vasoconstriction.
- Non-Patent Document 1 Non-Patent Document 2.
- This S1P has two functions as an intracellular second messenger and an intercellular mediator.
- S1P G protein-coupled receptor present on the cell membrane surface
- EDG E ndothelial D ifferentiation G ene
- the S1P3 antagonist is airway contraction, bronchial asthma, chronic obstructive pulmonary disease (COPD), emphysema, tracheal stenosis, diffuse panbronchiolitis, infection, connective tissue disease or Bronchitis associated with transplantation, diffuse hamartoma pulmonary vascular myomatosis, adult respiratory distress syndrome (ARDS), interstitial pneumonia, lung cancer, hypersensitivity pneumonitis, idiopathic interstitial pneumonia, pulmonary fibrosis, sepsis or It has been reported to be effective as a therapeutic or prophylactic agent for cytokine storm based on influenza virus or RS virus infection.
- COPD chronic obstructive pulmonary disease
- emphysema emphysema
- tracheal stenosis tracheal stenosis
- diffuse panbronchiolitis infection
- connective tissue disease or Bronchitis associated with transplantation diffuse hamartoma pulmonary vascular myomato
- Patent Documents 3 to 6 show that the S1P3 antagonist is arteriosclerosis, intimal thickening, solid tumor, diabetic retinopathy, rheumatoid arthritis, heart failure, ischemic reperfusion injury, cerebral vascular spasm after subarachnoid hemorrhage, coronary Angina pectoris or myocardial infarction caused by vascular spasm, glomerulonephritis, thrombosis, pulmonary edema such as ARDS, cardiac arrhythmia, eye disease, ocular hypertension, glaucoma, glaucomatous retinopathy, optic nerve It is also effective for symptom or macular degeneration.
- Non-Patent Documents 5 and 7 report that the S1P3 receptor is involved in multi-organ failure due to sepsis based on analysis using S1P3 knockout mice, and S1P3 antagonists are effective as a therapeutic or preventive agent for sepsis. It has been suggested that there is. In addition, it has been reported that S1P1 antagonists enhance vascular wall permeability and cause pulmonary edema (Non-patent Document 8).
- the treatment or prevention drug has a weak S1P1 antagonist action, preferably an S1P1 agonist action, and more preferably no action on the S1P1 receptor. It is desired.
- S1P receptor modulator for example, a compound represented by the general formula (A) described in Patent Document 1 is known.
- R 1 is a hydrogen atom, a halogen atom, an optionally substituted lower alkyl group having 1 to 4 carbon atoms, a hydroxy group, a phenyl group, an aralkyl group, or a lower alkoxy group having 1 to 4 carbon atoms.
- X is indicated O, S, SO, and SO 2
- Patent Document 1 does not include 2-aminophosphate monoester derivatives and 3-aminophosphonic acid derivatives having a diphenyl sulfide skeleton in which a hydroxyl group is substituted on a phenyl group. Further, it is not known that 2-aminophosphate monoester derivatives and 3-aminophosphonic acid derivatives having such a structure exhibit an excellent S1P3 receptor antagonistic action.
- Patent Document 6 discloses a compound represented by the general formula (B) as an S1P receptor modulator.
- R 1 represents a chlorine atom, a linear alkyl group having 1 to 3 carbon atoms or a trifluoromethyl group
- R 2 represents a fluorine atom or chlorine atom
- R 3 represents a carbon atom having 1 to 3 carbon atoms.
- X represents an oxygen atom or a sulfur atom
- n represents an integer of 2 or 3
- optically active compound represented by the general formula (Ba) has been reported to have a weak S1P3 agonistic action and an excellent agonistic action on S1P1 and / or S1P4.
- a compound having an asymmetric center opposite to the optically active compound represented by the general formula (Ba) is not known.
- it is not known that such an optically active compound exhibits an excellent S1P3 receptor antagonistic action.
- the problem to be solved by the present invention is to provide a diphenyl sulfide derivative having excellent S1P3 antagonist activity.
- the first invention relates to a diphenyl sulfide derivative represented by the general formula (1), a pharmacologically acceptable salt thereof, or a hydrate thereof.
- R 1 represents an alkoxy group having 1 to 6 carbon atoms
- R 2 represents a propyl group or an allyl group
- X represents a methylene or oxygen atom
- Z represents a halogen atom.
- the compound represented by the general formula (1) is a diphenyl sulfide derivative according to the first invention represented by the general formula (1a) or a pharmacologically acceptable salt thereof or a salt thereof. It relates to hydrates.
- the compound represented by the general formula (1) is (R) -2-allyl-2-amino-4- ⁇ 2-chloro-4- (5-ethoxy-2-hydroxyphenylthio). ) Phenyl ⁇ butyl phosphate monoester or (S) -2-amino-4- ⁇ 2-chloro-4- (5-ethoxy-2-hydroxyphenylthio) phenyl ⁇ -2-propylbutyl phosphate monoester
- the present invention relates to the diphenyl sulfide derivative according to the first invention or a pharmacologically acceptable salt thereof or a hydrate thereof.
- the fourth invention relates to a pharmaceutical comprising the diphenyl sulfide derivative according to any one of the first to third inventions, a pharmacologically acceptable salt thereof, or a hydrate thereof.
- the fifth invention also includes airway contraction, bronchial asthma, chronic obstructive pulmonary disease (COPD), emphysema, tracheal stenosis, diffuse panbronchiolitis, infection, connective tissue disease or bronchitis associated with transplantation, diffuse malpractice Pulmonary vascular myomatosis, adult respiratory distress syndrome (ARDS), interstitial pneumonia, lung cancer, hypersensitivity pneumonitis, idiopathic interstitial pneumonia, pulmonary fibrosis, sepsis or cytokines based on influenza virus or RS virus infection
- the present invention relates to the medicine according to the fourth invention, which is a storm treatment or prevention drug.
- the sixth invention is caused by arteriosclerosis, intimal thickening, solid tumor, diabetic retinopathy, rheumatoid arthritis, heart failure, ischemic reperfusion injury, cerebral vascular spasm after subarachnoid hemorrhage, coronary vascular spasm Treatment of angina pectoris or myocardial infarction, glomerulonephritis, thrombosis, lung disease caused by pulmonary edema, cardiac arrhythmia, eye disease, ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy or macular degeneration Or it is related with the pharmaceutical of the 4th invention which is a preventive agent.
- the seventh invention relates to the medicament according to the fourth invention, which is a therapeutic or prophylactic agent for sepsis.
- the eighth invention also relates to the diphenyl sulfide derivative according to any one of the first to third inventions, a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a pharmaceutically acceptable carrier.
- the present invention relates to a pharmaceutical composition containing *
- the present invention it is possible to provide a diphenyl sulfide derivative having an excellent S1P3 antagonistic action and S1P3 selectivity. Further, the diphenyl sulfide derivative of the present invention can be used safely as a medicine because it has weak or no hemolytic, tissue damage and central inhibitory action. Furthermore, the diphenyl sulfide derivative of the present invention is stable in an aqueous solution.
- the compounds of the present invention having these excellent properties are useful for treating sepsis, airway contraction, bronchial asthma, chronic obstructive pulmonary disease (COPD), emphysema, tracheal stenosis, diffuse panbronchiolitis, infection, connective tissue disease or transplantation.
- COPD chronic obstructive pulmonary disease
- bronchitis causes bronchitis, diffuse hamartoma pulmonary vascular myomatosis, adult respiratory distress syndrome (ARDS), interstitial pneumonia, lung cancer, hypersensitivity pneumonitis, idiopathic interstitial pneumonia, pulmonary fibrosis, influenza virus ⁇ Or cytokine storm (overproduction) caused by RS virus infection, arteriosclerosis, intimal thickening, solid tumor, diabetic retinopathy, rheumatoid arthritis, heart failure, ischemic reperfusion injury, brain after subarachnoid hemorrhage Angiogenesis or myocardial infarction caused by vascular spasm, coronary vascular spasm, glomerulonephritis, thrombosis, pulmonary edema caused by pulmonary edema such as ARDS, cardiac arrhythmia, eye disease, ocular hypertension Disease, glaucoma, glaucomatous retinopathy, are useful for the prevention or treatment of optic neuropathy or macular degeneration
- halogen atom in the present invention represents a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- C 1-6 alkoxy group examples include a methoxy group, an ethoxy group, an n-propoxy group, an n-butoxy group, an i-propoxy group, and a t-butoxy group.
- R 1 is preferably an alkoxy group having 1 to 6 carbon atoms, particularly preferably an ethoxy group, for the purpose of obtaining an excellent S1P3 antagonistic action and safety for a living body in the present invention.
- R 2 is preferably a propyl group or an allyl group.
- X is preferably a methylene or oxygen atom, particularly preferably an oxygen atom.
- Z is preferably a halogen atom, particularly preferably a chlorine atom.
- Examples of the pharmacologically acceptable salt in the present invention include acid addition such as hydrochloride, hydrobromide, acetate, trifluoroacetate, methanesulfonate, citrate or tartrate.
- Examples include salts or alkali addition salts such as sodium salt, potassium salt, calcium salt, magnesium salt or aluminum salt.
- a compound in which X is an oxygen atom that is, a compound represented by the general formula (1d) can be produced by, for example, the synthesis route A as shown below.
- R 1 represents an alkoxy group having 1 to 6 carbon atoms
- R 2 represents a propyl group or an allyl group
- Z represents a halogen atom.
- the optically active compound represented by the general formula (4) is obtained by combining the optically active compound represented by the general formula (2) and the compound represented by the general formula (3) in the presence of a base. It can be produced by acting (step A-1).
- R 3 represents an alkyl group having 1 to 6 carbon atoms, and R 2 is as described above]
- a a represents a general leaving group such as a halogen atom, a methanesulfonyloxy group, a paratoluenesulfonyloxy group, or a trifluoromethanesulfonyloxy group, and R 2 is as described above]
- the compound represented by the general formula (2) is first treated with a base at ⁇ 78 ° C. in a reaction solvent such as 1,4-dioxane, tetrahydrofuran or diethyl ether. Thereafter, the compound represented by the general formula (3) is allowed to act at ⁇ 78 ° C. on the resulting anion of the compound represented by the general formula (2), followed by gradually raising the temperature to room temperature.
- a reaction solvent such as 1,4-dioxane, tetrahydrofuran or diethyl ether.
- the compound represented by the general formula (3) is allowed to act at ⁇ 78 ° C. on the resulting anion of the compound represented by the general formula (2), followed by gradually raising the temperature to room temperature.
- n-butyllithium or lithium diisopropylamide preferably n-butyllithium can be used.
- the normal temperature means 15 to 25 ° C. as defined by the Japanese Pharmacopoeia.
- the optically active compound represented by the general formula (6) is obtained by combining the optically active compound represented by the general formula (4) and the compound represented by the general formula (5) in the presence of a base. It can be produced by acting (Step A-2).
- a b is a halogen atom, a methanesulfonyloxy group, shows a typical leaving group such as p-toluenesulfonyloxy group or a trifluoromethanesulfonyloxy group, R 2, R 3 and Z are described above Street]
- a c represents a typical leaving group such as halogen atom, methanesulfonyloxy group, p-toluenesulfonyloxy group or a trifluoromethanesulfonyloxy group
- a b and Z are as defined above]
- the compound represented by the general formula (4) is first treated with a base at ⁇ 78 ° C. in a reaction solvent such as 1,4-dioxane, tetrahydrofuran or diethyl ether. Thereafter, the compound represented by the general formula (5) is allowed to act on the anion of the compound represented by the general formula (4) at ⁇ 78 ° C., followed by gradually raising the temperature to room temperature.
- a reaction solvent such as 1,4-dioxane, tetrahydrofuran or diethyl ether.
- the compound represented by the general formula (5) is allowed to act on the anion of the compound represented by the general formula (4) at ⁇ 78 ° C., followed by gradually raising the temperature to room temperature.
- n-butyllithium or lithium diisopropylamide preferably n-butyllithium can be used.
- the compound represented by the general formula (7) in the synthesis route A can be produced by acid-hydrolyzing the compound represented by the general formula (6) and then protecting the amino group with a general protecting reagent. it can.
- R 4 represents a general amino protecting group, and A b , R 2 , R 3 and Z are as described above]
- R 4 in formula (7) is not particularly limited as long as it protects the amino group, but for example, an acyl group such as an acetyl group or a carbamate such as t-butoxycarbonyl or benzyloxycarbonyl can be used (step A). -3).
- acid hydrolysis is performed at room temperature on the compound represented by the general formula (6) in an inorganic acid or an organic acid or in a mixed solution of an inorganic acid or an organic acid and water or an organic solvent.
- hydrochloric acid or hydrobromic acid can be used as the inorganic acid.
- organic acid trifluoroacetic acid or the like can be used.
- organic solvent methanol, ethanol, tetrahydrofuran, 1,4-dioxane, ethyl acetate, or the like can be used.
- acid hydrolysis is preferably performed using an aqueous trifluoroacetic acid solution.
- the amino ester is reacted with an acid chloride or acid anhydride in a solvent at 0 ° C. to room temperature, and is represented by the general formula (7).
- an acid chloride or acid anhydride in a solvent at 0 ° C. to room temperature, and is represented by the general formula (7).
- the solvent ethyl acetate, tetrahydrofuran, N, N-dimethylformamide, 1,4-dioxane, methylene chloride, chloroform, methanol, ethanol, acetonitrile or the like can be used as the solvent.
- the acid chloride acetyl chloride or benzyloxycarbonyl chloride can be used.
- As the acid anhydride acetic anhydride or di-t-butyl dicarbonate can be used. Of these, it is preferable to carry out the reaction using di-t-butyl dicarbonate.
- the compound represented by the general formula (8) in the synthesis route A can be produced by reducing the compound represented by the general formula (7) (step A-4).
- the compound represented by the general formula (7) is reduced at a temperature of 0 ° C. to heating under reflux, preferably normal temperature, using a reducing agent.
- Reducing agents include borane or alkylborane derivatives such as 9-borabicyclo [3.3.1] nonane (9-BBN), diisobutylaluminum hydride ((iBu) 2 AlH), sodium borohydride (NaBH 4 ), hydrogenation Metal hydride complex compounds such as lithium boron (LiBH 4 ) or lithium aluminum hydride (LiAlH 4 ) can be used.
- the reducing agent is lithium borohydride.
- the compound represented by the general formula (10) in the synthesis route A can be produced by reacting the compound represented by the general formula (8) with the compound represented by the general formula (9).
- R 5 represents a hydrogen atom or a general protecting group for a phenolic hydroxyl group, and R 1 , R 2 , R 4 and Z are as described above]
- a general protecting group for a phenolic hydroxyl group is not particularly limited as long as it protects the phenolic hydroxyl group.
- a t-butoxycarbonyl group can be used (Step A-5).
- the reaction can be carried out at room temperature to under reflux using a catalyst in a reaction solvent such as toluene, N, N-dimethylformamide, 1,4-dioxane, tetrahydrofuran or diethyl ether in the presence of an inorganic base or an organic base.
- a reaction solvent such as toluene, N, N-dimethylformamide, 1,4-dioxane, tetrahydrofuran or diethyl ether
- a reaction solvent such as toluene, N, N-dimethylformamide, 1,4-dioxane, tetrahydrofuran or diethyl ether
- an inorganic base sodium carbonate or potassium t-butoxide can be used.
- organic base diisopropylethylamine or the like can be used.
- the catalyst may be a palladium compound such as tris (dibenzylideneacetone) dipalladium (0) or palladium (II) acetate, preferably tris (dibenzylideneacetone) dipalladium (0).
- a palladium compound such as tris (dibenzylideneacetone) dipalladium (0) or palladium (II) acetate, preferably tris (dibenzylideneacetone) dipalladium (0).
- 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene bis [2- (diphenylphosphino) phenyl] ether, 1,1′-bis (di-t-butylphosphino) ferrocene, etc.
- a phosphine compound can also be added to the reaction solvent as a reaction accelerator.
- the compound represented by the general formula (12) in the synthesis route A can be produced by reacting the compound represented by the general formula (10) with the compound represented by the general formula (11) (process) A-6).
- the reaction can be performed at 0 ° C. to room temperature in the presence of carbon tetrabromide and pyridine using no solvent or methylene chloride, chloroform, acetonitrile, ethyl acetate, tetrahydrofuran, or diethyl ether as a solvent.
- the compound represented by the general formula (1d) in the synthesis route A is produced by treating the compound represented by the general formula (12) with acid hydrolysis and / or a nucleophile such as trimethylsilyl bromide or trimethylsilyl iodide. (Step A-7).
- the reaction can be carried out at a reflux temperature in an inorganic acid such as hydrochloric acid or hydrobromic acid, or in a mixed solution of an organic solvent such as methanol or ethanol and an inorganic acid.
- an inorganic acid such as hydrochloric acid or hydrobromic acid
- an organic solvent such as methanol or ethanol and an inorganic acid.
- acetonitrile or methylene chloride may be used as a preferable reaction solvent, and trimethylsilyl bromide or trimethylsilyl iodide may be allowed to act at 0 ° C. to room temperature.
- the treatment using a nucleophile can be performed by combining trimethylsilyl chloride and sodium bromide or by combining trimethylsilyl chloride and sodium iodide.
- the compound represented by the general formula (7) in the synthetic route A can also be produced, for example, by the synthetic route B as shown below. ⁇ Synthetic route B>
- optically active compound represented by the general formula (14) in the synthesis route B is prepared by using the optically active compound represented by the general formula (13) and the compound represented by the general formula (5) in Step A- (Step B-1).
- optically active compound represented by the general formula (15) in the synthesis route B is prepared by using the optically active compound represented by the general formula (14) and the compound represented by the general formula (3) in Step A- 1 (step B-2).
- the compound represented by the general formula (7) in the synthesis route B can be produced by the same method as in the step A-3 using the compound represented by the general formula (15) (step B-3).
- the compound represented by the general formula (10) in the synthesis route A can also be produced, for example, by the synthesis route C as shown below. ⁇ Synthetic route C>
- optically active compound represented by the general formula (17) in the synthesis route C is prepared by using the optically active compound represented by the general formula (4) and the compound represented by the general formula (16) in the step A- (Step C-1).
- the compound represented by the general formula (18) in the synthesis route C can be produced by the same method as in the step A-3 using the compound represented by the general formula (17) (step C-2).
- the compound represented by the general formula (10) in the synthesis route C can be produced by the same method as in Step A-4 using the compound represented by the general formula (18) (Step C-3).
- the compound represented by the general formula (18) in the synthesis route C can also be produced, for example, by the synthesis route D as shown below. ⁇ Synthesis route D>
- optically active compound represented by the general formula (19) in the synthesis route D is prepared by using the optically active compound represented by the general formula (13) and the compound represented by the general formula (16) in Step A- (Step D-1).
- optically active compound represented by the general formula (20) in the synthesis route D is prepared by using the optically active compound represented by the general formula (19) and the compound represented by the general formula (3) in Step A- 1 (step D-2).
- the compound represented by General Formula (18) in Synthesis Route D can be produced by the same method as in Step A-3 using the compound represented by General Formula (20) (Step D-3).
- a compound in which R 1 is a cyano group or an acetyl group and R 5 is a general protecting group for phenol that is, represented by the general formula (10a).
- the compound can also be produced, for example, by the synthesis route E as shown below.
- R 1a represents an acetyl group or a cyano group
- R 5a represents a general protecting group for a phenolic hydroxyl group
- R 2 , R 4, and Z are as described above
- R 5a is not particularly limited as long as it protects a phenolic hydroxyl group.
- methyl group, benzyl group, methoxymethyl group, tetrahydropyranyl group, t-butyldimethylsilyl group, acetyl group or t-butoxycarbonyl Groups can be used.
- optically active compound represented by the general formula (22) in the synthesis route E is prepared by using the optically active compound represented by the general formula (8) and the compound represented by the general formula (21) in Step A- 5 by the same method.
- R 5b represents a general protecting group for a phenolic hydroxyl group, and R 2 , R 4 and Z are as described above.
- R 5b is not particularly limited as long as it protects the phenolic hydroxyl group.
- a methyl group, benzyl group, methoxymethyl group, tetrahydropyranyl group, t-butyldimethylsilyl group, acetyl group or t-butoxycarbonyl group can be used (step E-1).
- the compound represented by the general formula (23) in the synthesis route E can be produced by protecting the phenolic hydroxyl group of the compound represented by the general formula (22) (step E-2).
- the reaction is not particularly limited as long as it is a technique used for protecting a normal phenolic hydroxyl group.
- a chloride or acid chloride is added to the compound represented by the general formula (22) in the presence of an inorganic base or an organic base. It can be performed by reacting.
- the inorganic base potassium carbonate or the like can be used.
- the organic base triethylamine or diisopropylethylamine can be used.
- chloride methoxymethyl chloride, t-butyldimethylsilyl chloride, benzyl chloride or the like can be used.
- acid chloride acetyl chloride or the like can be used. Of these, it is preferable to protect the phenolic hydroxyl group using methoxymethyl chloride.
- the reaction can be carried out by reacting at 0 ° C. to room temperature.
- the compound represented by the general formula (24) in the synthesis route E can be produced by removing R 5b of the compound represented by the general formula (23) (step E-3).
- the reaction is not particularly limited as long as it is a method usually used for removing a protecting group of a phenolic hydroxyl group and R 5a is not removed.
- R 5b is a silyl protecting group such as a t-butyldimethylsilyl group.
- the deprotection reaction is carried out using a fluorine compound such as tetrabutylammonium fluoride or hydrogen fluoride-pyridine, preferably tetrabutylammonium fluoride, in a reaction solvent such as tetrahydrofuran, acetonitrile or methylene chloride. it can.
- the deprotection reaction can be performed at a temperature of 0 ° C. to heating under reflux, preferably 0 ° C.
- the compound represented by the general formula (25) in the synthesis route E can be produced by allowing N-phenyltrifluoromethanesulfonimide to act on the compound represented by the general formula (24) (step E-4). .
- a solvent such as methylene chloride, chloroform or toluene is used, and N-phenyltrifluoromethanesulfonimide is allowed to act at 0 ° C. to 80 ° C., preferably at room temperature, in the presence of an organic base such as pyridine or triethylamine. Can be done.
- the compound represented by the general formula (10a) in the synthesis route E is a known method using zinc cyanide from the compound represented by the general formula (25) (for example, Synth. Commun., 25, 3255-3261 (1995). )), Or a known method using the Heck reaction (for example, J. Org., Chem., 55, 3654-3655 (1990)) or the like (step E-5).
- R 1a is a cyano group.
- the reaction can be carried out in the presence of zinc cyanide in a reaction solvent such as toluene, N, N-dimethylformamide, 1,4-dioxane or tetrahydrofuran using a catalyst at a temperature from room temperature to heating to reflux.
- a catalyst a palladium compound such as tetrakistriphenylphosphine palladium (0) or tris (dibenzylideneacetone) dipalladium (0), preferably tetrakistriphenylphosphine palladium (0) can be used.
- a phosphine compound such as 1,1′-bis (diphenylphosphino) -ferrocene or 1,3-bis (diphenylphosphino) -propane can also be added as a reaction accelerator to the reaction solvent.
- R 1a is an acetyl group
- the reaction is carried out by reacting butyl vinyl ether in a solvent such as toluene, N, N-dimethylformamide, 1,4-dioxane or tetrahydrofuran using a catalyst and a reaction accelerator in the presence of an organic base.
- the organic base triethylamine or diisopropylethylamine can be used.
- palladium (II) acetate can be used as the catalyst.
- reaction accelerator 1,3-bis (diphenylphosphino) -propane can be used. The reaction can be carried out at a temperature ranging from room temperature to heating reflux.
- a compound in which X is methylene that is, a compound represented by the general formula (1e) can be produced by, for example, the synthesis route F shown below.
- the compound represented by the general formula (26) in the synthesis route F can be produced by oxidizing the compound represented by the general formula (10) (step F-1).
- a generally used oxidation method of alcohol to aldehyde can be used.
- oxidation treatment using a chromium oxide-pyridine complex such as pyridinium chlorochromate or pyridinium dichromate, or oxidation using hypervalent iodine such as Dess-Martin oxidation
- dimethyl sulfoxide oxidation using various dimethyl sulfoxide activators such as oxalyl chloride, trifluoroacetic anhydride, acetic anhydride, dicyclohexylcarbodiimide, or sulfur trioxide-pyridine complex can also be mentioned.
- the compound represented by the general formula (29) is, for example, a compound represented by the general formula (26) and a compound represented by the general formula (27) in a reaction solvent in the presence of a base. It can manufacture by making it react. (Step F-2).
- reaction sodium hydride, potassium hydride, sodium alkoxide, potassium alkoxide, n-butyllithium or the like, preferably n-butyllithium can be used.
- reaction solvent tetrahydrofuran, diethyl ether, 1,4-dioxane or the like can be used.
- the reaction temperature can be -78 ° C to room temperature.
- the compound represented by the general formula (30) in the synthesis route F can be produced by reducing the compound represented by the general formula (29) (step F-3).
- the reaction can be carried out in the presence of a catalytic reduction catalyst in a solvent such as ethanol, methanol, tetrahydrofuran, N, N-dimethylformamide or ethyl acetate at room temperature under normal to pressurized hydrogen pressure.
- a catalytic reduction catalyst palladium carbon, platinum carbon, platinum oxide, rhodium carbon, ruthenium carbon, or the like can be used.
- the reaction can also be carried out by diimide reduction.
- potassium azodicarboxylate in a solvent such as pyridine, ethanol, methanol, dimethyl sulfoxide, or 1,4-dioxane in the presence of acetic acid at a temperature from normal temperature to heating reflux.
- a solvent such as pyridine, ethanol, methanol, dimethyl sulfoxide, or 1,4-dioxane
- the compound represented by general formula (1e) in synthesis route F can be produced by the same method as in step A-7 using the compound represented by general formula (30) (step F-4).
- the diphenyl sulfide derivative of the present invention or a pharmacologically acceptable salt thereof or a hydrate thereof exhibits an excellent S1P3 antagonistic action and produces a medicament based on the sphingosine-1-phosphate 3 (S1P3) receptor antagonistic action
- S1P3 sphingosine-1-phosphate 3
- a pharmaceutical comprising at least one of these as an active ingredient is effective as a therapeutic or prophylactic agent for a disease for which an S1P3 antagonist is known to be effective as a therapeutic or prophylactic agent.
- COPD chronic obstructive pulmonary disease
- emphysema tracheal stenosis
- diffuse generalization Bronchitis infection
- connective tissue disease or bronchitis associated with transplantation diffuse hamartoma pulmonary vascular myomatos
- the medicament of the present invention is also effective for treating or preventing diseases that are known to have an effective S1P3 antagonistic action.
- Diseases for which the S1P3 antagonist action is known to be effective include, for example, arteriosclerosis, intimal thickening, solid tumors, diabetic retinopathy, rheumatoid arthritis, heart failure, ischemic reperfusion injury, subarachnoid hemorrhage Later cerebral vascular spasm, angina or myocardial infarction caused by coronary vascular spasm, glomerulonephritis, thrombosis, pulmonary edema such as ARDS, cardiac arrhythmia, eye disease, ocular hypertension, glaucoma Glaucomatous retinopathy, optic neuropathy or macular degeneration.
- the medicament of the present invention can be administered by oral means.
- the medicament of the present invention can also be administered by parenteral means such as rectal, subcutaneous, intravenous, intramuscular or transdermal.
- a pharmacologically acceptable salt thereof or a hydrate thereof as a pharmaceutical, it may be in the form of a solid composition, a liquid composition or other composition, and if necessary The best one is selected.
- the pharmaceutical composition of the present invention can also be produced by blending the compound of the present invention with a pharmacologically acceptable carrier. Specifically, conventional excipients, extenders, binders, disintegrants, coating agents, sugar coatings, pH adjusters, solubilizers or aqueous or non-aqueous solvents are added, and tablets are prepared by conventional formulation techniques. , Pills, capsules, granules, powders, powders, solutions, emulsions, suspensions or injections.
- N-Butyllithium-hexane was added to a solution of (5R) -2-allyl-3,6-dimethoxy-5-isopropyl-2,5-dihydropyrazine (3.64 g) in tetrahydrofuran (60 mL) at ⁇ 78 ° C. under an argon atmosphere. A solution (1.60 mol / L, 11.16 mL) was added to obtain a reaction solution. The reaction solution was stirred at ⁇ 78 ° C. for 30 minutes.
- a 50% trifluoroacetic acid-water solution (108 mL) was added to the compound of Reference Example 1 (5.44 g) to give a first reaction solution.
- the first reaction solution was stirred at room temperature for 1 hour and then allowed to stand overnight at room temperature.
- the first reaction solution was neutralized with a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate.
- the extract was washed with water and saturated brine, and dried over anhydrous sodium sulfate. After concentration of the extract, the residue was dissolved in acetonitrile (86 mL), and di-tert-butoxydicarbonate (11.0 g) was added to form a second reaction solution.
- Lithium borohydride (1.04 g) was added to a tetrahydrofuran (95 mL) solution of the compound of Reference Example 2 (6.16 g) while cooling with ice to prepare a reaction solution.
- ethanol 9 mL was added dropwise to the reaction solution, and the mixture was stirred for 2 hours while cooling with ice.
- a 10% aqueous citric acid solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate.
- the target product (35.6 g) was obtained as a colorless oil by reacting the compound of Reference Example 4 (53.4 g) in the same manner as in Reference Example 2.
- the organic layer was extracted with 1 mol / L aqueous sodium hydroxide solution, adjusted to pH 4 with concentrated hydrochloric acid, and extracted with diethyl ether.
- the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. After anhydrous sodium sulfate was removed by filtration, the solvent was distilled off under reduced pressure to obtain the desired product (12.1 g) as a colorless oil.
- Lithium aluminum hydride (119 mg) was added to a solution of the compound of Reference Example 9 (245 mg) in tetrahydrofuran (12.5 mL) while cooling with ice in an argon atmosphere to prepare a reaction solution. The reaction solution was stirred for 30 minutes while cooling with ice. To the reaction solution was added 1 mol / L hydrochloric acid, and the mixture was extracted with ethyl acetate, washed with water and saturated brine in that order, and then dried over anhydrous sodium sulfate. After anhydrous sodium sulfate was removed by filtration, the solvent was distilled off under reduced pressure to obtain the desired product (210 mg) as a colorless oil.
- the compound of Reference Example 10 (33.0 mg) was added to the reaction solution, and the mixture was heated to reflux for 14 hours, then water was added while cooling with ice, insolubles were filtered off using Celite, and washed with ethyl acetate. .
- a hydrogen chloride-methanol solution (5-10%, 15 mL) was added to the compound of Reference Example 15 (193 mg) to give a first reaction solution.
- the first reaction solution was stirred at room temperature for 1 day.
- acetonitrile (2.7 mL) was added under an argon atmosphere to obtain a second reaction solution.
- iodotrimethylsilane (0.19 mL) was added to the second reaction solution.
- the second reaction solution was stirred at the same temperature for 2 hours. After adding a large excess of cold water to the second reaction solution and removing the supernatant, the resulting brown oil was dissolved in methanol.
- the compound of Reference Example 17 (1.41 g) was dissolved in tetrahydrofuran (20 mL), and borane-tetrahydrofuran complex (1.01 mol / L tetrahydrofuran solution, 3.2 mL) was added dropwise while cooling with ice. It was. The reaction solution was stirred at the same temperature for 1.5 hours. Thereafter, water (20 mL) and sodium perborate monohydrate (644 mg) were added to the reaction solution while cooling with ice, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate.
- the compound of Reference Example 14 (122 mg) was dissolved in ethanol (2 mL), and 10% palladium-activated carbon (12 mg) was added to prepare a reaction solution.
- the reaction solution was stirred at room temperature for 10 hours under a hydrogen atmosphere (1 atm).
- the insoluble material was removed using celite, and the solvent of the filtrate was evaporated under reduced pressure to give the object product (123 mg) as a colorless oil.
- Tetrabutylammonium fluoride (1.0 mol / L tetrahydrofuran solution, 6.20 mL) was added to a tetrahydrofuran (31 mL) solution of the compound of Reference Example 23 (3.96 g) while cooling with ice to prepare a reaction solution. The reaction solution was stirred at the same temperature for 1 hour. Water was added to the reaction solution, and tetrahydrofuran was distilled off under reduced pressure, followed by extraction with ethyl acetate. The combined organic layers were washed successively with water (20 mL) and saturated brine, and dried over anhydrous sodium sulfate.
- the compound of Reference Example 24 (919 mg) was dissolved in ethanol (17.5 mL), 10% palladium-activated carbon (92 mg) was added, and the mixture was stirred at room temperature for 17.5 hours under a hydrogen atmosphere (1 atm). The solid was filtered through celite, and the solvent was evaporated under reduced pressure to give a residue (916 mg). This residue was dissolved in methanol (20 mL), 10% palladium-activated carbon (93 mg) was added, and the mixture was stirred at room temperature for 5 hours in a hydrogen atmosphere. 10% Palladium-activated carbon (92 mg) was added, and the mixture was further stirred for 14.5 hours.
- the compound of Reference Example 30 (525 mg) was dissolved in N, N-dimethylformamide (8.0 mL), n-butyl vinyl ether (0.512 mL, 3.99 mmol), triethylamine (0.112 mL), palladium acetate. (17.9 mg) and 1,3-bis (diphenylphosphino) propane (65.8 mg) were added to obtain a reaction solution. The reaction solution was stirred at 80 ° C. for 5.5 hours. While cooling with ice, 1 mol / L hydrochloric acid was added and stirred at room temperature for 1 hour. Water was added and ethyl acetate was extracted.
- the compound of Reference Example 37 (466 mg) was dissolved in dimethyl sulfoxide (4.2 mL), and triethylamine (1.2 mL) and sulfur trioxide-pyridine complex (669 mg) were added to prepare a reaction solution.
- the reaction solution was stirred at room temperature for 1.5 hours. Ice water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed successively with water and saturated brine, and dried over anhydrous sodium sulfate.
- tetramethyl methylenediphosphonate (201 mg) was dissolved in tetrahydrofuran (7 mL), and n-butyllithium (1.65 mol / L hexane solution, 0.52 mL) was added dropwise at -78 ° C to react. A liquid was used. The reaction solution was stirred at the same temperature for 30 minutes. A tetrahydrofuran solution (3 mL) of the compound of Reference Example 38 (367 mg) was added dropwise to the reaction solution at ⁇ 78 ° C., and the mixture was stirred at room temperature for 2 hours.
- the compound of Reference Example 39 (369 mg) was dissolved in pyridine (11 mL), and dipotassium azodicarboxylate (1.09 g) and acetic acid (0.48 mL) were added to give a reaction solution.
- the reaction solution was stirred at room temperature for 64 hours.
- Human S1P3 receptor-expressing CHO cells were subcultured in Ham's F-12 medium containing 10% fetal bovine serum and 300 ⁇ g / mL Geneticin.
- the human S1P3 receptor-expressing CHO cells were treated with 0.25% trypsin, recovered from the dish, and suspended in Ham's F-12 medium containing 10% fetal bovine serum and 300 ⁇ g / mL Geneticin. Then, were seeded in 96-well black clear bottom plates at the human S1P3 receptor expressing CHO cells is 2.5 x 10 4/100 ⁇ L / well (BD Falcon Biocoat), 37 °C, two nights cultured under 5% CO 2 did.
- Fluo3 loading buffer was prepared as follows. First, an equal amount of Fluo3-AMdo (Dojindo) and pluronic F-127 (20% DMSO solution, invitrogen) were mixed. Subsequently, the mixed solution of Fluo3-AM and pluronic F-127 was added to Hanks-HEPES buffer (20 M HEPES (pH7.4), 0.1% BSA (Fatty acid Free), 2.5 mM probenecid-containing Hanks balanced salt solution). In addition, the final concentration of Fluo3-AM at 4 ⁇ M was designated as Fluo3 loading buffer.
- test compound (0.125 nM, 1.25 nM, 12.5 nM, 125 nM, 1.25 ⁇ M) or the same buffer in which DMSO is dissolved, and in a microplate fluorescence spectrophotometer (FLEX Station (Molecular Device)) at 37 ° C. Incubated for 30 minutes.
- Human S1P1 receptor-expressing CHO cells were subcultured in Ham's F-12 medium containing 10% fetal bovine serum and 300 ⁇ g / mL Geneticin.
- the human S1P1 receptor-expressing CHO cells were treated with 0.25% trypsin, recovered from the dish, and suspended in Ham's F-12 medium containing 10% fetal bovine serum and 300 ⁇ g / mL Geneticin. Then, were seeded in 96-well black clear bottom plates at the human S1P1 receptor expressing CHO cells is 2.5 x 10 4/100 ⁇ L / well (BD Falcon Biocoat), 37 °C, two nights cultured under 5% CO 2 did.
- Fluo3 loading buffer was prepared as follows. First, an equal amount of Fluo3-AMdo (Dojindo) and pluronic F-127 (20% DMSO solution, invitrogen) were mixed. Subsequently, the mixed solution of Fluo3-AM and pluronic F-127 was added to Hanks-HEPES buffer (20 M HEPES (pH7.4), 0.1% BSA (Fatty acid Free), 2.5 mM probenecid-containing Hanks balanced salt solution). In addition, the final concentration of Fluo3-AM at 4 ⁇ M was designated as Fluo3 loading buffer.
- the EC 50 values of the compounds of Example 1 and Example 2 were greater than 10 ⁇ mol / L (> 10 ⁇ mol / L). Moreover, as a result of evaluating the antagonistic action of the S1P1 receptor using the method of Experimental Example 1, the Kd values of the compounds of Example 1 and Example 2 were 2.66 nmol / L and 1.60 nmol / L, respectively.
- Example 3 Sepsis model with cecal perforation
- Non-Patent Document 9 D. Rittirsch et al., Nature Protocols, 4, 31 (2009) was used as a reference.
- CLP cecal ligation and puncture
- the compound of the present invention exhibits an excellent antagonistic action on the human S1P3 receptor, but has a weaker or no antagonistic action or agonistic action on the human S1P1 receptor compared to the human S1P3 receptor antagonistic action. Became clear. It was also confirmed that the compound of the present invention has an excellent inhibitory effect on sepsis.
- the diphenyl sulfide derivative of the present invention it is possible to provide a diphenyl sulfide derivative having excellent S1P3 antagonist activity and S1P3 selectivity.
- the diphenyl sulfide derivative of the present invention can be safely used as a medicine because it has weak or no hemolysis, tissue damage, and central inhibitory action.
- the diphenyl sulfide derivative of the present invention is stable in an aqueous solution.
- the compound of the present invention having these excellent properties is used for bronchial constriction, bronchial asthma, chronic obstructive pulmonary disease (COPD), pulmonary emphysema, tracheal stenosis, diffuse panbronchiolitis, infection, connective tissue disease or bronchial associated with transplantation.
- COPD chronic obstructive pulmonary disease
- pulmonary emphysema pulmonary emphysema
- tracheal stenosis tracheal stenosis
- diffuse panbronchiolitis infection
- connective tissue disease or bronchial associated with transplantation bronchial associated with transplantation.
- Inflammation diffuse hamartoma pulmonary vascular myomatosis, adult respiratory distress syndrome (ARDS), interstitial pneumonia, lung cancer, hypersensitivity pneumonitis, idiopathic interstitial pneumonia, pulmonary fibrosis, sepsis, influenza virus, RS Caused by cytokine storm based on viral infection, arteriosclerosis, intimal thickening, solid tumor, diabetic retinopathy, rheumatoid arthritis, heart failure, ischemic reperfusion injury, cerebral vascular spasm after subarachnoid hemorrhage, coronary vascular spasm Lung diseases caused by pulmonary edema such as angina pectoris or myocardial infarction, glomerulonephritis, thrombosis, ARDS, cardiac arrhythmia, eye disease, ocular hypertension, glaucoma, glaucomatous retinopathy, Neurosis, and it is useful as a preventive or therapeutic agent for macular degeneration.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
は移植を原因とする気管支炎、びまん性過誤腫性肺脈管筋腫症、成人呼吸促迫症候群(ARDS)、間質性肺炎、肺癌、過敏性肺臓炎、特発性間質性肺炎、肺線維症、インフルエンザウイルス・もしくはRSウイルス感染を原因とするサイトカインストーム(過剰産生)、動脈硬化症、血管内膜肥厚、固形腫瘍、糖尿病性網膜症、関節リウマチ、心不全、虚血性再灌流障害、くも膜下出血後の脳血管スパズム、冠血管スパズムを原因とする狭心症または心筋梗塞、糸球体腎炎、血栓症、ARDSなどの肺浮腫を原因とする肺疾患、心不整脈、眼疾患、眼高血圧症、緑内障、緑内障性網膜症、視神経症または黄班変性症の予防または治療に有用である。
<合成経路A>
<合成経路B>
<合成経路C>
<合成経路D>
<合成経路E>
<合成経路F>
<参考例1>(2R,5R)-2-アリル-2-(4-ブロモ-2-クロロフェニル)エチル-3,6-ジメトキシ-5-イソプロピル-2,5-ジヒドロピラジン
1H NMR (CDCl3, 400 MHz): δ 0.69 (3H, d, J = 6.7 Hz), 1.10 (3H, d, J = 6.7 Hz), 1.79 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.02 (1H, ddd, J = 12.8, 11.6, 4.9 Hz), 2.27-2.48 (4H, m), 2.54 (1H, dd, J = 13.4, 7.3 Hz), 3.69 (3H, s), 3.70 (3H, s), 3.95 (1H, d, J = 3.1 Hz), 4.97 (1H, dd, 10.4, 2.4 Hz), 5.01 (1H, d, J = 17.7 Hz), 5.61-5.72 (1H, m), 7.01 (1H, d, J = 7.9 Hz), 7.27 (1H, dd, J = 7.9, 1.8 Hz), 7.47 (1H, d, J = 1.8 Hz).
ESIMS (+) : 441 [M+H] +.
<参考例2>(R)-2-アリル-4-(4-ブロモ-2-クロロフェニル)-2-t-ブトキシカルボニルアミノ酪酸メチル
1H NMR (CDCl3, 400 MHz): δ 1.45 (9H, s), 2.08 (1H, ddd, J = 13.4, 11.0, 5.5 Hz), 2.39-2.51 (2H, m), 2.51-2.61 (1H, m), 2.67 (1H, td, J = 12.8, 4.9 Hz), 3.00-3.14 (1H, m), 3.74 (3H, s), 5.07 (1H, d, J = 4.9 Hz), 5.10 (1H, s), 5.52-5.69 (1H, m), 7.03 (1H, d, J = 7.9 Hz), 7.29 (1H, dd, J = 7.9, 1.8 Hz), 7.48 (1H, d, J = 1.8 Hz).
ESIMS (+) : 446 [M+H] +.
<参考例3>(R)-2-[2-(4-ブロモ-2-クロロフェニル)エチル]-2-t-ブトキシカルボニルアミノ-4-ペンテン-1-オール
1H NMR (CDCl3, 400 MHz): δ 1.43 (9H, s), 1.80-1.94 (2H, m), 2.32 (1H, td, J = 14.1, 7.9 Hz), 2.44 (1H, dd, J = 14.1, 6.7 Hz), 2.63-2.77 (2H, m), 3.69-3.79 (2H, m), 4.09 (1H, br s), 4.72 (1H, s), 5.19 (1H, dd, J = 6.1, 1.8 Hz), 5.22 (1H, s), 5.80-5.91 (1H, s), 7.11 (1H, d, J = 7.9 Hz), 7.31 (1H, dd, J = 7.9, 1.8 Hz), 7.49 (1H, d, J = 1.8 Hz).
ESIMS (+) : 418 [M+H] +.
<参考例4>(2R,5R)-2-(4-ブロモ-2-クロロフェニル)エチル-3,6-ジメトキシ-5-イソプロピル-2-プロピル-2,5-ジヒドロピラジン
1H NMR (CDCl3, 400 MHz): δ 0.70 (3H, d, J = 6.7 Hz), 0.86 (3H, t, J = 7.3 Hz), 1.11 (3H, d, J = 6.7 Hz), 1.15-1.30 (2H, m), 1.49-1.62 (1H, m), 1.71-1.84 (2H, m), 1.98 (1H, td, J = 12.4, 4.8 Hz), 2.29-2.47 (3H, m), 3.69 (3H, s), 3.70 (3H, s), 3.95 (1H, d, J = 3.0 Hz), 7.01 (1H, d, J = 7.9 Hz), 7.27 (1H, dd, J = 7.9, 1.8 Hz), 7.46 (1H, d, J = 1.8 Hz).
ESIMS (+) :443 [M+H] +.
<参考例5>(S)-4-(4-ブロモ-2-クロロフェニル)-2-t-ブトキシカルボニルアミノ-2-プロピル酪酸メチル
1H NMR (CDCl3, 400 MHz): δ 0.89 (3H, t, J = 7.3 Hz). 0.96-1.10 (1H, m), 1.25-1.39 (1H, m), 1.46 (9H, s), 1.69 (1H, ddd, J = 13.9, 11.5. 4.8 Hz), 1.99-2.10 (1H, m), 2.20-2.35 (1H, m), 2.42 (1H, ddd, J = 13.9, 11.5, 4.8 Hz), 2.49-2.60 (1H, m), 2.64 (1H, td, J = 13.9, 4.8 Hz), 3.74 (3H, s), 5.62 (1H, br s), 7.03 (1H, d, J = 8.5 Hz), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 7.48 (1H, J = 1.8 Hz).
ESIMS (+) : 448 [M+H] +.
<参考例6>(R)-2-[2-(4-ブロモ-2-クロロフェニル)エチル]-2-t-ブトキシカルボニルアミノペンタン-1-オール
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.29-1.42 (2H, m), 1.44 (9H, s), 1.53-1.62 (2H, m), 1.81 (1H, ddd, J = 13.9, 11.5, 5.4 Hz), 1.93 (1H, ddd, J = 13.9, 11.5, 5.4 Hz), 2.59-2.75 (2H, m), 3.73 (2H, d, J = 6.7 Hz), 4.15 (1H, br s), 4.62 (1H, br s), 7.11 (1H, d, J = 7.9 Hz), 7.31 (1H, dd, J = 7.9, 1.8 Hz), 7.49 (1H, d, J = 1.8 Hz).
ESIMS (+) : 420 [M+H] +.
<参考例7>1-シクロプロピル-4-(メトキシメトキシ)ベンゼン
1H NMR (CDCl3, 400 MHz): δ 0.59-0.62 (2H, m), 0.86-0.93 (2H, m), 1.80-1.90 (1H, m), 3.47 (3H, s), 5.14 (2H, s), 6.94 (2H, dt, J = 9.2, 2.4 Hz), 7.01 (2H, dt, J = 9.2, 2.4 Hz).
EIMS (+) : 178 [M] +.
<参考例8>5-シクロプロピル-2-(メトキシメトキシ)ベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 0.61 (2H, dt, J = 6.1, 4.9 Hz), 0.86-0.92 (2H, m), 1.75-1.86 (1H. m), 3.50 (3H, s), 3.76 (1H, s), 5.20 (2H, s), 6.80 (1H, dd, J = 8.6, 2.4 Hz), 6.98 (1H, d, J = 8.6 Hz), 6.98 (1H, d, J = 2.4 Hz).
EIMS (+) : 210 [M] +.
<参考例9>6-エトキシ-1,3-ベンゾオキサチオール-2-オン
1H NMR (CDCl3, 400 MHz): δ 1.42 (3H, t, J = 6.7 Hz). 4.02 (2H, q, J = 6.7 Hz), 6.84 (1H, dd, J = 8.6, 2.4 Hz), 6.91 (1H, d, J = 2.4 Hz), 7.18 (1H, d, J = 8.6 Hz).
EIMS (+) : 196 [M] +.
<参考例10>5-エトキシ-2-ヒドロキシベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 1.38 (3H, t, J = 7.3 Hz). 3.10 (1H, s), 3.96 (2H, q, J = 7.3 Hz), 5.73 (1H, s), 6.78 (1H, dd, J = 9.2, 3.1 Hz), 6.87 (1H, d, J = 9.2 Hz), 6.98 (1H, d, J = 3.1 Hz).
EIMS (+) : 170 [M] +.
<参考例11>6-t-ブチルジメチルシリルオキシ-1,3-ベンゾオキサチオール-2-オン
1H NMR (CDCl3, 400 MHz): δ 0.20 (6H, s), 0.98 (9H, s), 6.77 (1H, dd, J = 8.6, 2.4 Hz), 6.87 (1H, d, J = 2.4 Hz), 7.14 (1H, d, J = 8.6 Hz).
CIMS (+) : 283 [M+H] +.
<参考例12>5-t-ブチルジメチルシリルオキシ-2-ヒドロキシベンゼンチオール
1H NMR (CDCl3, 400 MHz): δ 0.16 (6H, s), 0.97 (9H, s), 3.06 (1H, s), 5.73 (1H, s), 6.71 (1H, dd, J = 8.6, 2.4 Hz), 6.81 (1H, d, J = 2.4 Hz), 6.93 (1H, d, J = 8.6 Hz).
CIMS (+) : 257 [M+H] +.
<参考例13> (R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-エトキシ-2-ヒドロキシフェニルチオ)フェニル}ブタン-1-オール
1H NMR (CDCl3, 400 MHz) : δ 1.39 (3H, t, J = 6.7 Hz), 1.43 (9H, s), 1.77-1.91 (2H, m), 2.32 (1H, dd, J = 13.9, 7.9 Hz), 2.43 (1H, dd, J = 13.9, 7.3 Hz), 2.59-2.75 (2H, m), 3.67-3.79 (2H, m), 3.97 (2H, q, J = 6.7 Hz), 4.15 (1H, brs), 4.71 (1H, s), 5.17 (1H, d, J = 3.6 Hz), 5.21 (1H, s), 5.78-5.91 (1H, m), 6.04 (1H, s), 6.91 (1H, dd, J = 7.9, 1.8 Hz), 6.93-7.21 (1H, m).
ESIMS (+) : 508 [M+H]+.
<参考例14>(R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(2-t-ブトキシカルボニルヒドロキシ-5-エトキシフェニルチオ)フェニル}ブタン-1-オール
1H NMR (CDCl3, 400 MHz): δ 1.36 (3H, t, J = 7.3 Hz), 1.44 (9H, s), 1.51 (9H, s), 1.87 (2H, ddd, J = 11.5, 6.1, 1.8 Hz), 2.33 (1H, dd, J = 13.9, 8.5 Hz), 2.45 (1H, dd, J = 13.9, 6.7 Hz), 2.64-2.78 (2H, m), 3.68-3.81 (2H, m), 3.94 (2H, q, J = 7.3 Hz), 4.73 (1H, s), 5.19 (1H, d, J = 3.6 Hz), 5.22 (1H, s), 5.79-5.93 (1H, m), 6.78-6.84 (2H, m), 7.09 (1H, d, J = 8.5 Hz), 7.15 (2H, s), 7.33 (1H, s).
ESIMS (+) : 608 [M+H]+.
<参考例15> (R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(2-t-ブトキシカルボニルヒドロキシ-5-エトキシフェニルチオ)フェニル}-1-ジメトキシホスホリルオキシブタン
1H NMR (CDCl3, 400 MHz) :δ 1.36 (3H, t, J = 7.3 Hz), 1.44 (9H, s), 1.51 (9H, s), 1.75-1.92 (1H, m), 1.90-2.10 (1H, m), 2.42-2.57 (2H, m), 2.64-2.75 (2H, m), 3.77 (3H, s), 3.80 (3H, d, J = 1.2), 3.90-4.01 (2H, m), 4.11 (1H, dd, J = 9.7, 4.8 Hz), 4.22 (1H, dd, J = 9.7, 4.8 Hz), 4.60 (1H, brs), 5.17-5.25 (2H, m), 5.75-5.88 (1H, m), 6.78-6.84 (2H, m), 7.09 (1H, d, J = 8.5 Hz), 7.10-7.17 (2H, m), 7.32 (1H, t, J = 1.8 Hz).
ESIMS (+) : 716 [M+H]+.
旋光度 : [α]D 26 +2.74 (c 0.31, MeOH).
1H NMR (DMSO-d6, 400 MHz) : δ 1.23 (1H, t, J = 6.7 Hz), 1.60-1.77 (1H, m), 2.30-2.50 (1H, m), 2.62-2.73 (1H, m), 3.77 (2H, dt, J = 22.4, 12.1 Hz), 3.87 (2H, q, J = 6.7 Hz), 5.16-5.29 (2H, m), 5.77-5.84 (1H, m), 6.71 (1H, d, J = 2.4 Hz), 6.79-6.87 (2H, m), 7.07-7.14 (2H, m), 7.26 (1H, d, J = 7.9 Hz).
HRESIMS (+) : 488.10694 (C21H28ClNO6PSとして計算値488.10635).
<参考例16>(R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-シクロプロピル-2-メトキシメチルオキシフェニルチオ)フェニル}ブタン-1-オール
<参考例17>(R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-シクロプロピル-2-メトキシメチルオキシフェニルチオ)フェニル}-1-ジメトキシホスホリルオキシブタン
1H NMR (CDCl3, 400 MHz):δ0.57-0.60 (2H, m), 0.88-0.91 (2H, m), 1.44 (9H, s), 1.78-1.84 (2H, m), 1.96-2.04 (1H, m), 2.44-2.56 (2H, m), 2.68-2.73 (2H, m), 3.38 (3H, s), 3.77 (3H, s), 3.80 (3H, s), 4.12 (1H, dd, J = 9.8, 4.3 Hz), 4.23 (1H, dd, J = 9.8, 4.3 Hz), 4.59 (1H, brs), 5.15 (2H, s), 5.19-5.23 (2H, m), 5.76-5.85 (1H, m), 6.98 (1H, d, J = 8.6, 1.8 Hz), 7.00 (1H, d, J = 1.8 Hz), 7.08 (1H, d, J = 7.3 Hz), 7.09 (1H, d, J = 7.3 Hz), 7.17 (1H, d, J = 8.6 Hz), 7.23 (1H, d, J = 1.2 Hz).
ESIMS (+):656 [M+H]+.
<参考例18>(R)-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-シクロプロピル-2-メトキシメチルオキシフェニルチオ)フェニル}-1-ジメトキシホスホリルオキシ-2-(1-ヒドロキシプロピル)ブタン
1H NMR (CDCl3, 400 MHz):δ0.56-0.60 (2H, m), 0.87-0.92 (2H, m), 1.40 (9H, s), 1.60-1.66 (2H, m), 1.75-1.82 (4H, m), 2.68 (2H, t, J = 8.6 Hz), 3.38 (3H, s), 3.66-3.69 (2H, m), 3.78 (3H, d, J = 3.7 Hz), 3.80 (3H, d, J = 3.7 Hz), 4.12-4.16 (1H, m), 4.22-4.26 (1H, m), 4.61 (1H, brs), 5.15 (2H, s), 6.97 (1H, dd, J = 8.6, 2.5 Hz), 6.98 (1H, d, J = 8.6, 1.8 Hz), 7.00 (1H, d, J = 1.8 Hz), 7.06 (1H, d, J = 7.3 Hz), 7.09-7.12 (2H, m), 7.23 (1H, d, J = 1.8 Hz).
ESIMS (+):674 [M+H]+.
<参考例19> (R)-2-アミノ-4-{2-クロロ-4-(5-シクロプロピル-2-ヒドロキシフェニルチオ)フェニル}-2-(1-ヒドロキシプロピル)ブチルリン酸モノエステル
1H NMR (DMSO-d6, 400 MHz):δ0.49-0.53 (2H, m), 0.80-0.84 (2H, m), 1.46-1.81 (7H, m), 2.61 (2H, brs), 3.33-3.39 (2H, m), 3.71 (2H, brs), 6.85 (1H, d, J = 8.6 Hz), 6.92-6.99 (4H, m), 7.25 (1H, d, J = 7.3 Hz).
HRESIMS (+):502.12175 (C22H30ClNO6PS として計算値 502.12200).
<参考例20>(S)-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(2-t-ブトキシカルボニルオキシ-5-エトキシフェニルチオ)フェニル}-2-プロピルブタン-1-オール
1H NMR (CDCl3, 400 MHz):δ0.96 (3H, t, J = 7.3 Hz), 1.36 (3H, t, J = 7.3 Hz), 1.39-1.58 (4H, m), 1.51 (9H, s), 1.59 (9H, s), 1.53-1.60 (2H, m), 1.75-1.84 (1H, m), 1.86-1.95 (1H, m), 2.60-2.74 (2H, m), 3.74 (2H, d, J = 6.1 Hz), 3.94 (2H, q, J = 7.3 Hz), 4.22 (1H, brs), 4.64 (1H, brs), 6.78-6.83 (2H, m), 7.09 (1H, d, J = 8.6 Hz), 7.15-7.16 (1H, m), 7.33 (1H, d, J = 1.2 Hz).
ESIMS (+):610 [M+H]+.
<参考例21>(S)-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(2-t-ブトキシカルボニルオキシ-5-エトキシフェニルチオ)フェニル}-1-ジメトキシホスホリルオキシ-2-プロピルブタン
1H NMR (CDCl3, 400 MHz):δ0.95 (3H, t, J = 7.3 Hz), 1.47 (9H, s), 1.51 (9H, s), 1.63-1.82 (5H, m), 1.99-2.05 (1H, m), 2.64-2.69 (2H, m), 3.77 (3H, d, J = 1.2 Hz), 3.94 (2H, q, J = 7.3 Hz), 4.09-4.12 (1H, m), 4.23-4.26 (1H, m), 4.51 (1H, brs), 6.79-6.83 (2H, m), 7.09 (1H, d, J = 8.6 Hz), 7.12 (1H, d, J = 7.9 Hz), 7.15 (1H, dd, J = 7.9, 1.8 Hz), 7.33 (1H, d, J = 1.8 Hz).
ESIMS (+):718 [M+H]+.
旋光度:[α]D 28 -5.7 (c 0.34, MeOH).
旋光度:[α]D 25 +16.2 (c 0.5, DMF).
1H NMR (DMSO-d6, 400 MHz):δ0.89 (3H, t, J = 7.3 Hz), 1.23 (3H, t, J = 7.3 Hz), 1.29-1.32 (2H, m), 1.50-1.75 (4H, m), 2.61-2.66 (2H, m), 3.70-3.81 (2H, m), 3.87 (2H, q, J = 7.3 Hz), 6.71 (1H, d, J = 3.1 Hz), 6.82 (1H, dd, J = 8.6, 3.1 Hz), 6.86 (1H, d, J = 8.6 Hz), 7.10 (1H, dd, J = 8.0, 1.8 Hz), 7.12 (1H, d, J = 1.8 Hz), 7.28 (1H, d, J = 8.0 Hz).
HRESIMS (+):490.12195 (C21H30ClNO6PS として計算値 490.12200).
<参考例22>(R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-t-ブチルジメチルシリルオキシ-2-ヒドロキシフェニルチオ)フェニル}ブタン-1-オール
1H NMR (CDCl3, 400 MHz) : δ 0.17 (6H, s), 0.97 (9H, s), 1.58 (9H, s), 1.81-1.88 (2H, m), 2.32 (1H, dd, J = 13.5, 8.0 Hz), 2.43 (1H, dd, J = 13.5, 6.7 Hz), 2.62-2.70 (1H, m), 3.68-3.78 (2H, m), 4.71 (1H, brs), 5.17-5.21 (2H, m), 5.80-5.90 (1H, m), 6.05 (1H, s), 6.87-6.98 (4H, m), 7.03 (1H, d, J = 1.8 Hz), 7.10 (1H, d, J = 8.0 Hz).
ESIMS (+) : 594 [M+H]+.
<参考例23>(R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-t-ブチルジメチルシリルオキシ-2-メトキシメチルオキシフェニルチオ)フェニル}ブタン-1-オール
1H NMR (CDCl3, 400 MHz) : δ 0.08 (6H, s), 0.91 (9H, s), 1.44 (9H, s), 1.78-1.95 (2H, m), 2.34 (1H, dd, J = 14.1, 7.9 Hz), 2.46 (1H, dd, J = 14.1, 6.7 Hz), 2.65-2.82 (1H, m), 3.45 (3H, s), 3.68-3.82 (2H, m), 4.74 (1H, brs), 5.13 (2H, s), 5.16-5.25 (2H, m), 5.80-5.95 (1H, m), 6.53 (1H, d, J = 3.1 Hz), 6.68 (1H, dd, J = 9.2, 3.1 Hz), 7.00 (1H, d, J = 9.2 Hz), 7.18 (2H, s), 7.32 (1H, s).
ESIMS (+) : 638 [M+H]+.
<参考例24> (R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-ヒドロキシ-2-メトキシメチルオキシフェニルチオ)フェニル}ブタン-1-オール
1H NMR (CDCl3, 400 MHz) : δ 1.44 (9H, s), 1.80-2.03 (2H, m), 2.34 (1H, dd, J = 14.1, 7.9 Hz), 2.40-2.55 (1H, m), 2.70-2.85 (2H, m), 3.47 (3H, s), 3.65-3.78 (2H, m), 4.77 (1H, brs), 5.13 (2H, s), 5.17-5.27 (2H, m), 5.78-5.95 (1H, m), 6.45 (1H, s), 6.65 (1H, dd, J = 8.6, 3.1 Hz), 7.00 (1H, d, J = 8.6 Hz), 7.21 (2H, s), 7.38 (1H, s).
ESIMS (+) : 524 [M+H]+.
<参考例25> (R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(2-メトキシメチルオキシ-5-トリフルオロメタンスルホニルオキシフェニルチオ)フェニル}ブタン-1-オール
1H NMR (CDCl3, 400 MHz) : δ 1.44 (9H, s), 1.83-2.00 (2H, m), 2.34 (1H, dd, J = 14.1, 8.6 Hz), 2.47 (1H, dd, J = 14.1, 6.7 Hz), 2.70-2.87 (2H, m), 3.47 (3H, s), 3.70-3.85 (2H, m), 4.75 (1H, brs), 5.18-5.26 (2H, m), 5.24 (2H, s), 5.80-5.96 (1H, m), 6.78 (1H, d, J = 3.1 Hz), 7.05 (1H, dd, J = 9.2, 3.1 Hz), 7.16 (1H, d, J = 9.2 Hz), 7.27 (2H, s), 7.43 (1H, d, J = 1.2 Hz).
ESIMS (+) : 656 [M+H]+.
<参考例26> (R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-シアノ-2-メトキシメチルオキシフェニルチオ)フェニル}ブタン-1-オール
1H NMR (CDCl3, 400 MHz) : δ 1.45 (9H, s), 1.85-2.04 (2H, m), 2.36 (1H, dd, J = 13.9, 8.5 Hz), 2.47 (1H, dd, J = 13.9, 6.7 Hz), 2.70-2.86 (2H, m), 3.45 (3H, s), 3.70-3.84 (2H, m), 4.76 (1H, brs), 5.17-5.26 (2H, m), 5.29 (2H, s), 5.81-5.97 (1H, m), 7.13-7.21 (2H, m), 7.23-7.32 (2H, m), 7.42 (1H, d, J = 1.2 Hz), 7.45 (1H, dd, J = 8.5, 1.8 Hz).
ESIMS (+) : 533 [M+H]+.
<参考例27> (R)-2-アリル-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-シアノ-2-メトキシメチルオキシフェニルチオ)フェニル}-1-ジメトキシホスホリルオキシブタン
1H NMR (CDCl3, 400 MHz) : δ 1.38 (9H, s), 1.60-1.73 (1H, m), 1.75-1.90 (1H m), 2.35-2.44 (2H, m), 2.62-2.72 (2H, m), 3.25 (3H, s), 3.65 (3H, d, J = 1.2 Hz), 3.68 (3H, d, J = 1.2 Hz), 3.95-4.05 (1H, m), 4.05-4.18 (1H, m), 5.08-5.20 (2H, m), 5.35 (2H, s), 5.68-5.84 (1H, m), 6.70 (1H, brs), 7.25-7.36 (3H, m), 7.39 (1H, d, J = 1.8 Hz), 7.46 (1H, d, J = 1.8 Hz), 7.63 (1H, dd, J = 8.6, 2.4 Hz).
ESIMS (+) : 641 [M+H]+.
<参考例28> (R)-2-アリル-2-アミノ-4-{2-クロロ-4-(5-シアノ-2-ヒドロキシフェニルチオ)フェニル}ブチルリン酸モノエステル
旋光度 : [α]D 25 -9.0 (c 0.50, MeOH).1H NMR (DMSO-d6, 400 MHz) : δ 1.60-1.82 (2H, m), 2.30-2.42 (2H m), 2.62-2.80 (2H, m), 3.68-3.88 (2H, m), 5.14-5.30 (2H, m), 5.72-5.90 (1H, m), 7.06 (1H, d, J = 8.5 Hz), 7.14 (1H, dd, J = 8.5, 1.8 Hz), 7.26 (1H, d, J = 1.8 Hz), 7.31 (1H, d, J = 8.5 Hz), 7.50 (1H, d, J = 1.8 Hz), 7.62 (1H, dd, J = 8.5, 1.8 Hz).HRESIMS (+) : 469.07566 (C20H23ClN2O5PS として計算値 469.07538).
<参考例29>(S)-2-t-ブトキシカルボニルアミノ-4-[2-クロロ-4-(5-ヒドロキシ-2-メトキシメチルオキシフェニルチオ)フェニル]-2-プロピルブタン-1-オール
1H NMR (CDCl3, 400 MHz): δ 0.97 (3H, t, J = 7.3 Hz), 1.31-1.47 (2H, m), 1.44 (9H, s), 1.49-1.64 (2H, m), 1.83-2.02 (2H, m), 2.63-2.81 (2H, m), 3.48 (3H, s), 3.70 (2H, d, J = 6.1 Hz), 4.33 (1H, brs), 4.65 (1H, brs), 4.95 (1H, brs), 5.14 (2H, s), 6.37-6.45 (1H, m), 6.64 (1H, dd, J = 8.6, 2.4 Hz), 7.01 (1H, d, J = 8.6 Hz), 7.20-7.25 (2H, m), 7.38-7.42 (1H, m).
ESIMS (+) : 526 [M+H] +.
<参考例30> (S)-2-t-ブトキシカルボニルアミノ-4-[2-クロロ-4-(2-メトキシメチルオキシ-5-トリフルオロメタンスルホニルオキシフェニルチオ)フェニル]-2-プロピルブタン-1-オール
1H NMR (CDCl3, 400 MHz): δ 0.97 (3H, t, J = 7.3 Hz), 1.31-1.49 (2H, m), 1.44 (9H, s), 1.56-1.61 (2H, m), 1.80-1.88 (1H, m), 1.91-1.99 (1H, m), 2.67-2.80 (2H, m), 3.47 (3H, s), 3.75 (2H, d, J = 5.5 Hz), 4.22 (1H, brs), 4.66 (1H, s), 5.24 (2H, s), 6.78 (1H, d, J = 2.8 Hz), 7.05 (1H, dd, J = 9.2, 2.8 Hz), 7.16 (1H, d, J = 9.2 Hz), 7.25-7.28 (2H, m), 7.43 (1H, s).
ESIMS (+) : 658 [M+H] +.
<参考例31>(S)-2-t-ブトキシカルボニルアミノ-4-[2-クロロ-4-(5-シアノ-2-メトキシメチルオキシフェニルチオ)フェニル]-2-プロピルブタン-1-オール
1H NMR (CDCl3, 400 MHz): δ 0.98 (3H, t, J = 7.3 Hz), 1.31-1.45 (2H, m), 1.45 (9H, s), 1.56-1.62 (2H, m), 1.83-1.90 (1H, m), 1.94-2.02 (1H, m), 2.68-2.81 (2H, m), 3.46 (3H, s), 3.75-3.77 (2H, m), 4.20 (1H, brs), 4.66 (1H, s), 5.29 (2H, s), 7.15 (1H, d, J = 2.4 Hz), 7.17 (1H, d, J = 8.6 Hz), 7.25-7.28 (2H, m), 7.43 (1H, d, J = 1.5 Hz), 7.46 (1H, dd, J = 8.6, 1.5 Hz).
ESIMS (+) : 535 [M+H] +.
<参考例32> (S)-4-[4-(5-アセチル-2-メトキシメチルオキシフェニルチオ)-2-クロロフェニル]-2-t-ブトキシカルボニルアミノ-2-プロピルブタン-1-オール
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.30-1.44 (2H, m), 1.44 (9H, s), 1.55-1.59 (2H, m), 1.77-1.85 (1H, m), 1.89-1.96 (1H, m), 2.50 (3H, s), 2.62-2.75 (2H, m), 3.38 (3H, s), 3.72-3.74 (2H, m), 4.21 (1H, brs), 4.65 (1H, s), 5.27 (2H, s), 7.14-7.20 (3H, m), 7.30 (1H, d, J = 1.8 Hz), 7.83 (1H, d, J = 2.1 Hz), 7.87 (1H, dd, J = 8.6, 2.1 Hz).
ESIMS (+) : 552 [M+H] +.
<参考例33>(S)-2-t-ブトキシカルボニルアミノ-4-[2-クロロ-4-(5-シアノ-2-メトキシメチルオキシフェニルチオ)フェニル]-1-ジメトキシホスホリルオキシ-2-プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.97 (3H, t, J = 7.3 Hz), 1.34-1.45 (2H, m), 1.45 (9H, s), 1.63-1.76 (2H, m), 1.80-1.87 (1H, m), 2.02-2.10 (1H, m), 2.70-2.78 (2H, m), 3.45 (3H, s), 3.79 (3H, d, J = 11.0 Hz), 3.80 (3H, d, J = 11.0 Hz), 4.13 (1H, dd, J = 9.8, 4.3 Hz), 4.27 (1H, dd, J = 9.8, 4.3 Hz), 4.54 (1H, brs), 5.29 (2H, s), 7.14 (1H, d, J = 1.8 Hz), 7.17 (1H, d, J = 8.6 Hz), 7.25-7.27 (2H, m), 7.42 (1H, d, J = 1.8 Hz), 7.46 (1H, dd, J = 8.6, 1.8 Hz).
ESIMS (+) : 643 [M+H] +.
<参考例34>(S)-4-[4-(5-アセチル-2-メトキシメチルオキシフェニルチオ)-2-クロロフェニル]-2-t-ブトキシカルボニルアミノ-1-ジメトキシホスホリルオキシ-2-プロピルブタン
1H NMR (CDCl3, 400 MHz): δ 0.96 (3H, t, J = 7.3 Hz), 1.31-1.42 (2H, m), 1.44 (9H, s), 1.59-1.71 (2H, m), 1.74-1.82 (1H, m), 1.97-2.07 (1H, m), 2.50 (3H, s), 2.64-2.72 (2H, m), 3.38 (3H, s), 3.78 (3H, d, J = 11.0 Hz), 3.79 (3H, d, J = 11.0 Hz), 4.11 (1H, dd, J = 9.8, 4.9 Hz), 4.25 (1H, dd, J = 9.8, 4.9 Hz), 4.52 (1H, brs), 5.27 (2H, s), 7.15-7.16 (2H, m), 7.19 (1H, d, J = 8.6 Hz), 7.30 (1H, d, J = 1.8 Hz), 7.84 (1H, d, J = 2.1 Hz), 7.88 (1H, dd, J = 8.6, 2.1 Hz).
ESIMS (+) : 660 [M+H] +.
<参考例35>(S)-2-アミノ-4-[2-クロロ-4-(5-シアノ-2-ヒドロキシフェニルチオ)フェニル]-2-プロピルブチルリン酸モノエステル
1H NMR (DMSO-d6, 400 MHz): δ 0.88 (3H, t, J = 7.3 Hz), 1.25-1.36 (2H, m), 1.48-1.61 (2H, m), 1.67-1.78 (2H, m), 2.63-2.67 (2H, m), 3.70-3.81 (2H, m), 7.07 (1H, d, J = 8.6 Hz), 7.14 (1H, dd, J = 8.6, 1.8 Hz), 7.26 (1H, d, J = 1.8 Hz), 7.32 (1H, d, J = 8.6 Hz), 7.48 (1H, d, J = 2.1 Hz), 7.61 (1H, dd, J = 8.6, 2.1 Hz).
HRESIMS (+) : 471.09108(C20H25ClN2O5PSとして計算値471.09103).
<参考例36> (S)-4-[4-(5-アセチル-2-ヒドロキシフェニルチオ)-2-クロロフェニル]-2-アミノ-2-プロピルブチルリン酸モノエステル
1H NMR (DMSO-d6, 400 MHz): δ 0.88 (3H, t, J = 7.3 Hz), 1.24-1.37 (2H, m), 1.51-1.62 (2H, m), 1.68-1.77 (2H, m), 2.44 (3H, s), 2.62-2.66 (2H, m), 3.76-3.85 (2H, m), 7.04 (1H, d, J = 8.6 Hz), 7.10 (1H, dd, J = 8.6, 1.8 Hz), 7.16 (1H, d, J = 1.8 Hz), 7.29 (1H, d, J = 8.6 Hz), 7.79 (1H, d, J = 2.1 Hz), 7.85 (1H, dd, J = 8.6, 2.1 Hz).
HRESIMS (+) : 488.10680 (C21H28ClNO6PSとして計算値488.10635).
<参考例37> (S)-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-エトキシ-2-メトキシメチルオキシフェニルチオ)フェニル}-2-プロピルブタン-1-オール
1H NMR (CDCl3, 400 MHz):δ0.96 (3H, t, J = 7.3 Hz), 1.35 (3H, t, J = 6.7 Hz), 1.38-1.42 (1H, m), 1.44 (9H, s), 1.55-1.60 (1H, m), 1.78-1.85 (1H, m), 1.88-1.98 (1H, m), 3.44 (3H, s), 3.74 (2H, q, J = 6.7 Hz), 4.15 (1H, brs), 4.63 (1H, brs), 5.12 (2H, s), 6.69 (1H, d, J = 3.1 Hz), 7.77 (1H, dd, J = 9.2, 3.1 Hz), 7.07 (1H, d, J = 9.2 Hz), 7.16-7.17 (2H, m), 7.31-7.32 (1H, m).
ESIMS (+):554 [M+H] +.
<参考例38> (S)-2-t-ブトキシカルボニルアミノ-4-{2-クロロ-4-(5-エトキシ-2-メトキシメチルオキシフェニルチオ)フェニル}-2-プロピルブタン-1-アール
1H NMR (CDCl3, 400 MHz):δ0.90 (3H, t, J = 7.3 Hz), 1.08-1.10 (1H, m), 1.25-1.32 (1H, m), 1.35 (3H, t, J = 6.7 Hz), 1.46 (9H, s), 1.59-1.68 (1H, m), 1.96-2.01 (1H, m), 2.12-2.18 (1H, m), 2.43-2.49 (2H, m), 2.57-2.62 (1H, m), 3.44 (3H, s), 3.92 (2H, q, J = 6.7 Hz), 5.12 (2H, s), 5.38 (1H, brs), 6.70 (1H, d, J = 3.1 Hz), 6.76 (1H, dd, J = 9.2, 3.1 Hz), 7.06-7.10 (2H, m), 7.14 (1H, dd, J = 8.0, 1.8 Hz), 7.30 (1H, d, J = 3.1 Hz), 9.31 (1H, s).
ESIMS (+):552 [M+H] +.
<参考例39> (S)-3-t-ブトキシカルボニルアミノ-5-{2-クロロ-4-(5-エトキシ-2-メトキシメチルオキシフェニルチオ)フェニル}-3-プロピル-1-ペンテニルホスホン酸ジメチルエステル
1H NMR (CDCl3, 400 MHz):δ0.93 (3H, t, J = 7.3 Hz), 1.30-1.32 (4H, m), 1.35 (3H, t, J = 6.7 Hz), 1.44 (9H, s), 1.67-1.77 (1H, m), 2.01-2.09 (1H, m), 2.56-2.68 (2H, m), 3.46 (3H, m), 3.72 (3H, s), 3.75 (3H, s), 3.92 (2H, q, J = 7.3 Hz), 5.12 (2H, s), 5.67 (1H, t, J = 17.7 Hz), 6.69-6.77 (3H, m), 7.07 (1H, d, J = 7.3 Hz), 7.11 (1H, d, J = 8.0 Hz), 7.15 (1H, dd, J = 8.0, 1.8 Hz), 7.31 (1H, d, J = 1.8 Hz).
ESIMS (+):658 [M+H] +.
<参考例40> (S)-3-t-ブトキシカルボニルアミノ-5-{2-クロロ-4-(5-エトキシ-2-メトキシメチルオキシフェニルチオ)フェニル}-3-プロピルペンチルホスホン酸ジメチルエステル
1H NMR (CDCl3, 400 MHz):δ0.95 (3H, t, J = 7.3 Hz), 1.24-1.56 (4H, m), 1.35 (3H, t, J = 7.3 Hz), 1.43 (9H, s), 1.69-1.77 (2H, m), 1.85-2.10 (3H, m), 2.60-2.64 (2H, m), 3.44 (3H, m), 3.73 (3H, s), 3.76 (3H, s), 3.92 (2H, q, J = 7.3 Hz), 4.27 (1H, brs), 5.12 (2H, s), 6.69 (1H, d, J = 3.1 Hz), 6.76 (1H, dd, J = 9.2, 3.1 Hz), 7.07 (1H, d, J = 9.2 Hz), 7.12 (1H, d, J = 8.0 Hz), 7.16 (1H, dd, J = 8.0, 1.8 Hz), 7.31 (1H, d, J = 1.8 Hz).
ESIMS (+):660 [M+H] +.
旋光度:[α]D 23 +1.8 (c 0.32, MeOH).
1H NMR (DMSO-d6, 400 MHz):δ0.88 (3H, t, J = 7.3 Hz), 1.23 (3H, t, J = 6.7 Hz), 1.29 (2H, brs), 1.54 (4H, brs), 1.70-1.81 (4H, m), 2.61 (2H, brs), 3.87 (2H, q, J = 6.7 Hz), 6.70 (1H, d, J = 3.1 Hz), 6.80-6.88 (2H, m), 7.09-7.12 (2H, m), 7.28 (1H, d, J = 8.0 Hz).
HRESIMS (+):488.14296 (C22H32ClNO5PS として計算値 488.14273).
<実験例1> S1P(スフィンゴシン-1-リン酸)によるヒトS1P3受容体発現細胞の細胞内カルシウム動員に対する被験化合物の抑制作用
<実験例3>盲腸穿孔結さつ敗血症モデル
Claims (8)
- 前記一般式(1)で示される化合物が、(R)-2-アリル-2-アミノ-4-{2-クロロ-4-(5-エトキシ-2-ヒドロキシフェニルチオ)フェニル}ブチルリン酸モノエステル、又は(S)-2-アミノ-4-{2-クロロ-4-(5-エトキシ-2-ヒドロキシフェニルチオ)フェニル}-2-プロピルブチルリン酸モノエステルである請求項1記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物。
- 請求項1~3のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物を含む医薬。
- 気道収縮、気管支喘息、慢性閉塞性肺疾患(COPD)、肺気腫、気管狭窄症、びまん性汎細気管支炎、感染、結合組織病もしくは移植に伴う気管支炎、びまん性過誤腫性肺脈管筋腫症、成人呼吸促迫症候群(ARDS)、間質性肺炎、肺癌、過敏性肺臓炎、特発性間質性肺炎、肺線維症、敗血症、またはインフルエンザウイルスもしくはRSウイルス感染に基づくサイトカインストームの治療又は予防薬である請求項4記載の医薬。
- 動脈硬化症、血管内膜肥厚、固形腫瘍、糖尿病性網膜症、関節リウマチ、心不全、虚血性再灌流障害、くも膜下出血後の脳血管スパズム、冠血管スパズムを原因とする狭心症もしくは心筋梗塞、糸球体腎炎、血栓症、肺浮腫を原因とする肺疾患、心不整脈、眼疾患、眼高血圧症、緑内障、緑内障性網膜症、視神経症または黄班変性症の治療又は予防薬である請求項4記載の医薬。
- 敗血症の治療又は予防薬である請求項4記載の医薬。
- 請求項1~3のうち何れか1つに記載のジフェニルスルフィド誘導体若しくは薬理学的に許容されるその塩又はそれらの水和物及び薬学的に許容されうる担体を含有する医薬組成物。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020137018833A KR20140020240A (ko) | 2010-12-21 | 2011-12-20 | 다이페닐설파이드 유도체 및 이것을 유효성분으로 하는 의약품 |
CN201180061536.9A CN103261209B (zh) | 2010-12-21 | 2011-12-20 | 二苯硫醚衍生物和含有其作为活性成分的药品 |
SG2013037569A SG190816A1 (en) | 2010-12-21 | 2011-12-20 | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient |
JP2012549635A JP5795333B2 (ja) | 2010-12-21 | 2011-12-20 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
US13/883,847 US8993543B2 (en) | 2010-12-21 | 2011-12-20 | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient |
BR112013015701A BR112013015701A2 (pt) | 2010-12-21 | 2011-12-20 | derivado de sulfeto difelina, medicamento e composição farmacêutica contendo o referido derivado |
AU2011346254A AU2011346254B2 (en) | 2010-12-21 | 2011-12-20 | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient |
NZ610866A NZ610866A (en) | 2010-12-21 | 2011-12-20 | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient |
CA2817688A CA2817688A1 (en) | 2010-12-21 | 2011-12-20 | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient |
EP11850843.1A EP2657241B1 (en) | 2010-12-21 | 2011-12-20 | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient |
RU2013133810/04A RU2566296C2 (ru) | 2010-12-21 | 2011-12-20 | Производное дифенилсульфида и фармацевтический продукт, который содержит его в качестве активного ингредиента |
MX2013005568A MX2013005568A (es) | 2010-12-21 | 2011-12-20 | Derivado de sulfuro de difenilo y producto farmaceutico que contiene el mismo como ingrediente activo. |
IL226048A IL226048A (en) | 2010-12-21 | 2013-04-29 | Sulfur diphenyl derivative and a pharmaceutical product containing it as an active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-284150 | 2010-12-21 | ||
JP2010284150 | 2010-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012086184A1 true WO2012086184A1 (ja) | 2012-06-28 |
Family
ID=46313476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/007111 WO2012086184A1 (ja) | 2010-12-21 | 2011-12-20 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8993543B2 (ja) |
EP (1) | EP2657241B1 (ja) |
JP (1) | JP5795333B2 (ja) |
KR (1) | KR20140020240A (ja) |
CN (1) | CN103261209B (ja) |
AU (1) | AU2011346254B2 (ja) |
BR (1) | BR112013015701A2 (ja) |
CA (1) | CA2817688A1 (ja) |
CL (1) | CL2013001329A1 (ja) |
CO (1) | CO6700877A2 (ja) |
IL (1) | IL226048A (ja) |
MX (1) | MX2013005568A (ja) |
MY (1) | MY161036A (ja) |
NZ (1) | NZ610866A (ja) |
RU (1) | RU2566296C2 (ja) |
SA (1) | SA111330084B1 (ja) |
SG (1) | SG190816A1 (ja) |
TW (1) | TWI519539B (ja) |
WO (1) | WO2012086184A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015194157A1 (ja) * | 2014-06-16 | 2015-12-23 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体の製造方法及び製造中間体 |
WO2016013225A1 (ja) * | 2014-07-24 | 2016-01-28 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体の製造方法及び製造中間体 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020313A1 (fr) | 2001-09-04 | 2003-03-13 | Ono Pharmaceutical Co., Ltd. | Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate |
WO2003029184A1 (fr) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur |
WO2003029205A1 (fr) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur |
WO2004026817A1 (ja) | 2002-09-19 | 2004-04-01 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
WO2004074297A1 (ja) | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
WO2005044478A2 (en) | 2003-10-20 | 2005-05-19 | International Resistive Company | Resistive film on aluminum tube |
JP2005247691A (ja) | 2004-03-01 | 2005-09-15 | Toa Eiyo Ltd | S1p3受容体拮抗薬 |
WO2006063033A2 (en) | 2004-12-06 | 2006-06-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
WO2007043568A1 (ja) | 2005-10-12 | 2007-04-19 | Toa Eiyo Ltd. | S1p3受容体拮抗剤 |
WO2008018427A1 (fr) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif |
JP2010013407A (ja) * | 2008-07-04 | 2010-01-21 | Kyorin Pharmaceut Co Ltd | アミノアルコール誘導体 |
JP2010077053A (ja) * | 2008-09-25 | 2010-04-08 | Kyorin Pharmaceut Co Ltd | フェノール誘導体及びそれらを有効成分とする医薬 |
WO2011004604A1 (ja) * | 2009-07-09 | 2011-01-13 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
JP2011032226A (ja) * | 2009-08-03 | 2011-02-17 | Kyorin Pharmaceutical Co Ltd | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
WO2011138393A1 (en) * | 2010-05-06 | 2011-11-10 | Novartis Ag | Treatment of autoimmune diseases |
WO2011138398A1 (en) * | 2010-05-06 | 2011-11-10 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090318389A1 (en) | 2006-08-04 | 2009-12-24 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1 phosphate receptor |
-
2011
- 2011-11-28 TW TW100143514A patent/TWI519539B/zh not_active IP Right Cessation
- 2011-12-19 SA SA111330084A patent/SA111330084B1/ar unknown
- 2011-12-20 MX MX2013005568A patent/MX2013005568A/es active IP Right Grant
- 2011-12-20 US US13/883,847 patent/US8993543B2/en not_active Expired - Fee Related
- 2011-12-20 RU RU2013133810/04A patent/RU2566296C2/ru not_active IP Right Cessation
- 2011-12-20 BR BR112013015701A patent/BR112013015701A2/pt not_active IP Right Cessation
- 2011-12-20 AU AU2011346254A patent/AU2011346254B2/en not_active Ceased
- 2011-12-20 KR KR1020137018833A patent/KR20140020240A/ko not_active Application Discontinuation
- 2011-12-20 CN CN201180061536.9A patent/CN103261209B/zh not_active Expired - Fee Related
- 2011-12-20 EP EP11850843.1A patent/EP2657241B1/en active Active
- 2011-12-20 SG SG2013037569A patent/SG190816A1/en unknown
- 2011-12-20 MY MYPI2013001735A patent/MY161036A/en unknown
- 2011-12-20 NZ NZ610866A patent/NZ610866A/en not_active IP Right Cessation
- 2011-12-20 CA CA2817688A patent/CA2817688A1/en not_active Abandoned
- 2011-12-20 WO PCT/JP2011/007111 patent/WO2012086184A1/ja active Application Filing
- 2011-12-20 JP JP2012549635A patent/JP5795333B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-29 IL IL226048A patent/IL226048A/en not_active IP Right Cessation
- 2013-05-14 CL CL2013001329A patent/CL2013001329A1/es unknown
- 2013-05-16 CO CO13120944A patent/CO6700877A2/es active IP Right Grant
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020313A1 (fr) | 2001-09-04 | 2003-03-13 | Ono Pharmaceutical Co., Ltd. | Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate |
WO2003029184A1 (fr) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur |
WO2003029205A1 (fr) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur |
WO2004026817A1 (ja) | 2002-09-19 | 2004-04-01 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
WO2004074297A1 (ja) | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
WO2005044478A2 (en) | 2003-10-20 | 2005-05-19 | International Resistive Company | Resistive film on aluminum tube |
JP2005247691A (ja) | 2004-03-01 | 2005-09-15 | Toa Eiyo Ltd | S1p3受容体拮抗薬 |
WO2006063033A2 (en) | 2004-12-06 | 2006-06-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
WO2007043568A1 (ja) | 2005-10-12 | 2007-04-19 | Toa Eiyo Ltd. | S1p3受容体拮抗剤 |
WO2008018427A1 (fr) | 2006-08-08 | 2008-02-14 | Kyorin Pharmaceutical Co., Ltd. | Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif |
JP2010013407A (ja) * | 2008-07-04 | 2010-01-21 | Kyorin Pharmaceut Co Ltd | アミノアルコール誘導体 |
JP2010077053A (ja) * | 2008-09-25 | 2010-04-08 | Kyorin Pharmaceut Co Ltd | フェノール誘導体及びそれらを有効成分とする医薬 |
WO2011004604A1 (ja) * | 2009-07-09 | 2011-01-13 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
JP2011032226A (ja) * | 2009-08-03 | 2011-02-17 | Kyorin Pharmaceutical Co Ltd | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
WO2011138393A1 (en) * | 2010-05-06 | 2011-11-10 | Novartis Ag | Treatment of autoimmune diseases |
WO2011138398A1 (en) * | 2010-05-06 | 2011-11-10 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
Non-Patent Citations (12)
Title |
---|
D. CHRISTINA ET AL., AM.J.PATHOL., vol. 170, no. 1, 2007, pages 281 |
D. RITTIRSCH ET AL., NATURE PROTOCOLS, vol. 4, 2009, pages 31 |
F. NISSEN ET AL., NATURE, vol. 452, 2008, pages 654 |
F.NISSEN ET AL., BLOOD, vol. 113, no. 12, 2009, pages 2859 |
H. OKAZAKI ET AL., BIOCHEM. BIOPHS. RES. COMMUN., vol. 190, 1993, pages 1104 |
J. ORG., CHEM, vol. 55, 1990, pages 3654 - 3655 |
M.G.SANNA ET AL., NATURE CHEMICAL BIOLOGY, vol. 2, 2006, pages 434 |
See also references of EP2657241A4 |
SYNTH. COMMUN., vol. 25, 1995, pages 3255 - 3261 |
Y. GON, PROC NATL ACAD SCI U S A., vol. 102, no. 26, 2005, pages 9270 |
Y. IGARASHI, ANN, N.Y. ACAD. SCI., vol. 845, 1998, pages 19 |
Y. TAKUMA ET AL., MOL. CELL. ENDOCRINOL., vol. 177, 2001, pages 3 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015194157A1 (ja) * | 2014-06-16 | 2015-12-23 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体の製造方法及び製造中間体 |
WO2016013225A1 (ja) * | 2014-07-24 | 2016-01-28 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体の製造方法及び製造中間体 |
Also Published As
Publication number | Publication date |
---|---|
CL2013001329A1 (es) | 2014-02-07 |
JPWO2012086184A1 (ja) | 2014-05-22 |
SA111330084B1 (ar) | 2014-07-02 |
CN103261209B (zh) | 2016-07-13 |
EP2657241A4 (en) | 2014-07-02 |
RU2013133810A (ru) | 2015-01-27 |
US8993543B2 (en) | 2015-03-31 |
AU2011346254A1 (en) | 2013-06-06 |
CO6700877A2 (es) | 2013-06-28 |
TWI519539B (zh) | 2016-02-01 |
TW201307373A (zh) | 2013-02-16 |
JP5795333B2 (ja) | 2015-10-14 |
RU2566296C2 (ru) | 2015-10-20 |
IL226048A0 (en) | 2013-06-27 |
CN103261209A (zh) | 2013-08-21 |
BR112013015701A2 (pt) | 2016-10-11 |
EP2657241A1 (en) | 2013-10-30 |
AU2011346254B2 (en) | 2016-08-04 |
MX2013005568A (es) | 2013-08-26 |
NZ610866A (en) | 2015-01-30 |
IL226048A (en) | 2016-04-21 |
US20130261089A1 (en) | 2013-10-03 |
SG190816A1 (en) | 2013-07-31 |
CA2817688A1 (en) | 2012-06-28 |
KR20140020240A (ko) | 2014-02-18 |
MY161036A (en) | 2017-04-14 |
EP2657241B1 (en) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2058317B1 (en) | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient | |
US20100016258A1 (en) | Phosphonate derivatives as autotaxin inhibitors | |
EP2922859A1 (en) | Phosphonucleosides useful in the treatment of viral disorders | |
EP2364089A1 (en) | Heterobicyclic sphingosine 1-phosphate analogs | |
JP5616342B2 (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
JP5795333B2 (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
JP2010077053A (ja) | フェノール誘導体及びそれらを有効成分とする医薬 | |
JP2011032226A (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
JP2012131725A (ja) | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 | |
EA003677B1 (ru) | Алифатические аминокарбоновые и аминосульфоновые кислоты, аминонитрилы и аминотетразолы как агенты сохранения клеток |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11850843 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012549635 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2817688 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013001329 Country of ref document: CL |
|
REEP | Request for entry into the european phase |
Ref document number: 2011850843 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13120944 Country of ref document: CO Ref document number: 2011850843 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/005568 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2011346254 Country of ref document: AU Date of ref document: 20111220 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13883847 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137018833 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013133810 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013015701 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013015701 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130620 |